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2. ABBREVIATIONS 
BPD  bronchopulmonary dysplasia 
BSID  Bayley Scales of Infant Development 
BW  birth weight 
CA  corrected age 
CI  confidence interval 
CP  cerebral palsy 
CPAP   continuous positive airway pressure 
ELBW   extremely low birth weight 
ELGA   extremely low gestational age 
EPT  extremely preterm 
FT  full-term 
GA  gestational age 
GMFCS Gross Motor Function Classification System 
GW  gestational week(s) 
IQ  intelligence quotient 
IQR  interquartile range 
IRR  incidence rate ratio 
MDI  Mental Developmental Index 
MV  mechanical ventilation 
NDI  neurodevelopmental impairment 
NEC  necrotising enterocolitis 
NICU  neonatal intensive care unit 
OR  odds ratio 
PDI  Psychomotor Developmental Index 
PDA  patent ductus arteriosus 
PIVH  peri/intraventricular haemorrhage 
PMA  postmenstrual age 
PPROM preterm premature rupture of the membranes 
PSOM  Paediatric Stroke Outcome Measure 
PVL  periventricular leucomalacia 
QALY  quality-adjusted life years 
RDS  respiratory distress syndrome 
RI  respiratory infection(s) 
ROP  retinopathy of prematurity 
RW  recurrent wheezing 
SD  standard deviation 
SGA  small for gestational age 
VLBW  very low birth weight 
VLGA  very low gestational age 
VPT  very preterm  
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3. INTRODUCTION 
Advances in perinatal care have improved the survival of very preterm (VPT; 
born at <32 completed gestational weeks (GW) and/or with birth weight (BW) 
1500 g) infants dramatically (Fanaroff et al. 2003). However, survival and 
later neurological and developmental outcomes for these infants, especially for 
extremely preterm (EPT, born at 28 GW and/or BW 1000 g) infants, remain 
of concern because of significant mortality and morbidity rates. About 1 to 
1.5% of all births is at 32 GW, but these infants account for one third to one 
half of all neonatal and infant deaths (EURO-PERISTAT Project 2010). Ad-
ditionally they remain at substantial risk for a wide spectrum of long-term 
morbidities (Saigal and Doyle 2008), which leads to high emotional and eco-
nomic costs for their families (van der Pal et al. 2007) and for society (Phibbs 
and Schmitt 2006, Korvenranta et al. 2010). 
Providing quality care is a core principal of modern healthcare. Advances in 
perinatal care of VPT infants have resulted in improvements in gestation-speci-
fic survival rates such that, in the developed countries as well as in Estonia, 
mortality is no longer a particularly useful measurement of quality of care. If 
the aim of neonatal care is to achieve long-term survival free of handicap, then 
it is mandatory that any assessment of the quality of care for VPT infants must 
include the long-term outcome for these infants. It is important to document the 
long-term outcomes of survivors of VPT births and to link this to events within 
the perinatal period. In general, 2 years corrected for gestational age (GA) at 
birth is considered an acceptable time for collecting initial follow-up data about 
VPT infants. At this age, it is likely that the findings will still be relevant to 
current clinical practice, and the effects of social and demographic factors are 
minimised (Lyon 2007). Healthcare and health-system factors also play a role in 
outcome for VPT infants more generally. For VPT births, delivery in a tertiary 
level maternity unit with an onsite tertiary level neonatal intensive care is as-
sociated with lower mortality (Poets et al. 2004, Marlow et al. 2014). It has also 
been shown that long-term health outcomes for EPT infants are better if they 
receive their whole initial neonatal care in tertiary level units (Rautava et al. 
2013). 
Population-based study designs and standardised data collection have been 
recommended for the evaluation of perinatal care services, as well as for studies 
of prognosis (Evans and Levene 2001, Marlow 2003). Since the introduction of 
antenatal steroids and postnatal surfactant therapy in perinatal treatment of VPT 
infants, studies from developed countries have presented population-based as 
well as nationwide short-term and long-term outcomes for VPT and EPT in-
fants. However, although some data are available, no nationwide studies have 
been published that relate to Eastern European countries, which have more 
limited resources and less experience in the care of EPT infants than the 
developed countries. 
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In Estonia, the only previously published data with respect to the outcome of 
VPT infants are for infants with a BW less than 1500 g born in 19992000 at 
the infants' age of 3 years (Ormisson et al. 2009). Therefore, the studies of the 
present thesis were undertaken with the primary objectives to, first, describe the 
short-term and long-term outcome for VPT infants in Estonia after introduction 
of modern perinatal and neonatal care, and second, to benchmark altogether the 
quality of healthcare services for these vulnerable infants in Estonia and to 
identify key areas for ongoing national quality improvement initiatives.  
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4. REVIEW OF LITERATURE 
4.1. Epidemiology of preterm birth 
Definitions of preterm birth 
In humans, gestational length to non-elective delivery has been estimated at 282–
283 days (Bergsjo et al. 1990). Preterm birth occurs before 37 completed GW 
(World Health Organization 1977) and could further be subdivided into 
moderately preterm, VPT, and EPT (Figure 1). Definitions in the literature vary, 
but the limit of VPT birth is often set at <32 completed GW, whereas infants born 
at <28 completed GW are considered EPT. There has been no general agreement 
on the lower limit for defining preterm infants, or that used to distinguish preterm 
birth from spontaneous abortion. However, the lower limit at 22 completed GW is 
used in collecting birth register data and in calculation of perinatal mortality in 
many countries (Macfarlane et al. 2003), including Estonia. 
 
 
Preterm birth 
<37 GW 
Term birth 
3741 GW 
Postterm birth 
≥42 GW 
 
Extremely 
preterm 
<28 GW 
Very  
preterm 
2831 GW 
Moderately 
preterm 
3236 GW 
 
Figure 1. Categorisation of GA by completed GW at birth 
 
 
In previous research, the definitions of low, very low, and extremely low BW of 
<2500 g, <1500 g, and <1000 g, respectively, have been widely used as proxys 
for preterm birth. However, studies defining preterm births solely on BW crite-
ria are limited by some degree of misclassification as growth restricted infants 
with more advanced GA are probably over represented in such studies. It is thus 
better practice to define outcome by GA and then to study the effect of foetal 
growth restriction in these defined populations (Marlow 2004). 
To determine GA at birth, it is necessary to date the pregnancy and calculate 
the expected date of delivery, most commonly as 280 days from the first day of 
the last menstrual period. Despite problems of recalling the correct date of the last 
menstrual period, the estimations of GA are reasonably good (Savitz et al. 2002) 
and can be used in perinatal epidemiology research when other dating methods 
are unavailable. A more accurate way to date the pregnancy is to measure foetal 
size in early pregnancy, within the first trimester, using ultrasound techniques 
(Kramer et al. 1988). Importantly, changing the pregnancy dating method from 
last menstrual period to ultrasound could have an impact on GA distribution, 
leading to an increase in preterm birth rate (Goldenberg et al. 1989). Hence, rates 
of preterm birth may not be comparable if these are based on different methods of 
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estimating GA; publications reporting foetal and neonatal outcomes should 
clearly describe methods used to determine GA (Engle 2004). 
In the following text, infants born with a GA of <32 weeks or a BW of 
<1500 g are referred to as very low gestational age (VLGA) or very low birth 
weight (VLBW) infants, whereas infants born with a GA of <28 weeks or a BW 
of <1000 g are referred to as extremely low gestational age (ELGA) or extre-
mely low birth weight (ELBW) infants. In general, VLGA and VLBW infants 
are taken together as VPT infants and ELGA and ELBW infants as EPT infants. 
 
Age terminology during the perinatal period 
Standardised terminology should be used when defining ages and comparing 
outcomes of foetuses and VPT infants. The recommended terms by American 
Academy of Paediatrics (Engle 2004) are (Figure 2): 
 GA (completed weeks): time elapsed between the first day of the last menst-
rual period and the day of delivery. If pregnancy was achieved using assisted 
reproductive technology, GA is calculated by adding 2 weeks to the con-
ceptional age. 
 Chronological age (days, weeks, months, or years): time elapsed from birth. 
 Postmenstrual age (PMA) (weeks): GA plus chronological age. 
 Corrected age (CA) (weeks, months, or years): chronological age reduced by 
the number of weeks the infant was born before 40 GW; the term should be 
used only for children up to 3 years of age who were born VPT. 
During the perinatal period and neonatal hospital stay, PMA is preferred to 
describe the age of preterm infants. After the perinatal period, CA is the re-
commended term. 
 
 
 
Figure 2. Age terminology during the perinatal period (Engle 2004) 
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Rates of preterm births 
In 2010, an estimated 14.9 million babies (uncertainty range 12.318.1 million) 
were born preterm, 11.1% of all live births worldwide (Blencowe et al. 2012). 
In Estonia, the prevalence of preterm births was the highest at 6.6% in 1992 
and the lowest at 5.3% in 2010 (National Institute for Health Development 
2014). This is low in comparison with the international prevalence of preterm 
births in developed countries; a preterm birth rate of 12.7% has been reported in 
the United States of America (Heron et al. 2010) and the prevalence ranges 
from 5 to 10% in Europe (EURO-PERISTAT Project 2010). In developing 
countries, rates are even higher. A study from Malawi reported that 20% of 
women delivered preterm (van den Broek et al. 2005). 
Blencowe et al. has estimated time trends for preterm birth rates for 65 
countries in the developed world, Latin America, and the Caribbean regions. 
Only three countries, one of them Estonia, had reductions in estimated preterm 
birth rates from 1990 to 2010 (Blencowe et al. 2012). Rates of preterm birth 
were stable in 14 countries and increased in 48 countries. Much of the increase 
in the singleton preterm birth rate is explained by rising numbers of indicated 
preterm births. A high number of multiple gestations associated with assisted 
reproductive technologies are also an important contributor to the overall in-
crease in preterm births whereas singleton pregnancies after in-vitro fertilisation 
are also at increased risk of preterm birth (Jackson et al. 2004). 
From 1992 to 2011, the rate of VLGA births in Estonia stayed between 1.0 
and 1.3% (National Institute for Health Development 2014). This compares 
favourably to the rate of VLGA births in other parts of Europe, which varies 
from 0.7% in Iceland to 1.7% in the Northern United Kingdom (Field et al. 
2009, EURO-PERISTAT Project 2010). The prevalence of VLBW births in the 
United States of America stands at 1.6% (Mathews and MacDorman 2008). 
 
Risk factors for preterm birth 
The obstetric precursors leading to preterm birth are: 1) delivery for maternal or 
foetal indications, in which labour is either induced or the infant is delivered by 
pre-labour (elective) caesarean section; 2) spontaneous preterm labour with 
intact membranes; and 3) preterm premature rupture of the membranes 
(PPROM), irrespective of whether delivery is vaginal or by caesarean section 
(Goldenberg et al. 2008). 
Common reasons for indicated preterm births include pre-eclampsia or 
eclampsia, and intrauterine growth restriction (Goldenberg et al. 2008). Births 
that follow spontaneous preterm labour and PPROM  together called sponta-
neous preterm births  are regarded as a syndrome resulting from multiple 
causes, including infection or inflammation, uteroplacental ischaemia or hae-
morrhage, uterine over distension, stress, and other immunologically mediated 
processes (Romero et al. 2006, Romero et al. 2014). The precursors vary by GA 
(Mueller-Heubach et al. 1990, Steer 2005), with the precise cause of sponta-
neous preterm labour being unidentified in up to half of all cases (Menon 2008). 
There are many maternal and foetal characteristics that have been associated 
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with preterm birth, including maternal demographic characteristics (young or 
advanced age, black race, low socioeconomic and educational status, single 
marital status, absence of health insurance), nutritional status (low body-mass 
index), pregnancy history (a previous preterm birth, short inter-pregnancy 
intervals), present pregnancy characteristics (multiple pregnancy, vaginal 
bleeding caused by placental abruption or placenta praevia, cervical insufficien-
cy, extremes of the volume of amniotic fluid), psychological characteristics 
(clinical depression during pregnancy), and adverse behaviours (smoking, 
heavy alcohol consumption) (Goldenberg et al. 2008). Family history of pre-
term birth is a strong risk factor as well (Plunkett and Muglia 2008). Maternal 
medical disorders, such as thyroid disease, asthma, diabetes, and hypertension, 
are associated with increased rates of preterm delivery, many of which are 
indicated because of maternal complications (Goldenberg et al. 2008). How-
ever, there is abundant evidence that infection and the inflammation generated 
by infection, whether within the gestational tissues or elsewhere, are a primary 
cause of a substantial proportion of preterm births (Goldenberg et al. 2000, 
Agrawal and Hirsch 2012). The mechanisms by which intrauterine infections 
lead to preterm labour are related to activation of the innate immune system 
(Romero et al. 2006, Agrawal and Hirsch 2012, Ferguson 2014). 
Nowadays, it is recognised increasingly that previous understanding of pre-
term delivery has been limited by the failure to accept the idea that preterm 
birth is a syndrome with a number of etiologic factors and phenotypic charac-
teristics, many of which are independent of each other (Villar et al. 2012, 
Romero 2014). Therefore, Villar and his colleagues propose a classification that 
is based on clinical phenotypes that are defined by ≥1 characteristics of the 
mother, the foetus, the placenta, the signs of parturition, and the pathway to 
delivery (Villar et al. 2012). They describe five components in a preterm birth 
phenotype: 1) maternal conditions that are present before presentation for 
delivery; 2) foetal conditions that are present before presentation for delivery;  
3) placental pathologic conditions; 4) signs of the initiation of parturition; and 
5) the pathway to delivery. 
Previously social variations in low BW and preterm birth have been studied 
in Estonia. The birth-register studies from the 1990s showed that maternal age 
<20 years (Haldre et al. 2007) and low education as well as marital status 
(single mother) and nationality (non-Estonians) were all independently related 
to the risk of preterm birth (Koupilova et al. 2000). However, a recent study of 
time trends of socio-demographic determinants of preterm birth in Estonia 
during 19922010 (Varendi 2012) showed that since the re-establishment of the 
Estonian Republic in 1991, the proportion of preterm birth has decreased among 
parents at the age above 30 years, with primary or basic education, and of non-
Estonian nationality. Single status remained a risk factor for preterm delivery, 
as unregistered cohabiting and rural living had lost their importance (Figure 3). 
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Figure 3. Trends of preterm deliveries among maternal socio-demographic determi-
nants in Estonia (Varendi 2012) 
 
 
4.2. The changing face of intensive care  
for preterm infants 
Neonatal care before 1965 
Ironically, the history of neonatology began with innovative French midwives 
and obstetricians, not with paediatricians. Parisian obstetrician Stephane Tarnier 
modified a warming chamber for the rearing of poultry to develop the Tarnier-
Martin Couveuse in 1878, an isolette that decreased the neonatal death rate to 
38 from 66% for infants with BW less than 2000 g. Nevertheless, it was not 
until the 1950s and 1960s that premature baby units became established in a 
number of large hospitals emphasising the importance of 24-hour nursing care. 
Along with the establishment of autopsy services, it became apparent that the 
principal causes of death were immaturity, respiratory distress with histological 
evidence of hyaline membrane disease in the lungs, and intracranial hae-
morrhage (Wyatt 2010). Until the end-1950s, the primary support for respi-
ratory distress was the provision of high inspired oxygen concentrations. Con-
sequently, many preterm infants developed retrolental fibroplasia, now called 
retinopathy of prematurity (ROP), a disease virtually unknown before 1940s, 
but in the early 1950s it had become the leading cause of blindness in children 
in the United States of America (Philip 2005). 
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1965 to 1985 
The 1960s are considered to be the start of current modern practise of neonatal 
medicine, and the time when the premature nursery became a neonatal intensive 
care unit (NICU). Development of techniques to measure arterial blood gas 
levels and the development of intermittent positive pressure ventilation in 
preterm infants contributed to the more accurate assessment and aggressive 
management of respiratory disorders (Wyatt 2010). It was determined that the 
term respiratory distress syndrome (RDS) was more appropriate than hyaline 
membrane disease, as the last was a pathologic diagnosis. Because of the un-
certain cause, “idiopathic” was frequently placed before RDS. Chronic lung 
disease, bronchopulmonary dysplasia (BPD), first described by Northway 
(Northway et al. 1967), was increasingly recognised in survivors who had re-
ceived mechanical ventilation (MV), leading to many weeks or months of 
oxygen dependency and hospital care. The use of continuous positive airway 
pressure (CPAP) to prevent alveolar collapse was introduced in the United 
States of America in the 1970s (Gregory et al. 1971) and nasal CPAP has grown 
in importance as a mean of providing minimally invasive respiratory support.  
Peri/intraventricular haemorrhage (PIVH) was known to be a common 
autopsy finding in VPT babies who died in the first days of life, but it was 
thought to be a catastrophic event. However, in the late 1970s it became pos-
sible to image the infant brain during life, with the introduction of computed 
tomography, and since the 1980s, with real-time cranial ultrasound (Wyatt 
2010). It became apparent that there was a disturbingly high incidence of PIVH 
in VLBW survivors and numerous follow-up studies were started worldwide to 
relate cranial ultrasound findings in the neonatal period with long-term neuro-
logical and developmental outcomes (Stewart et al. 1987). Real-time ultrasound 
scanning made it also possible to document the evolution of periventricular 
leucomalacia (PVL), an ischemic lesion in periventricular white matter, and 
thus to define the clinical neurological correlates in the neonatal period (Dolfin 
et al. 1984). 
A concept of regionalisation was introduced and methods for transporting 
sick infants by ambulances were being established. The comparative data 
indicated that mortality and morbidity were higher in infants who had been 
transferred to centres postnatally in comparison with those who had been born 
at the centre (Usher 1971). When mothers were transferred to the centre to 
deliver, the data showed that such maternal-foetal transfers had mortality and 
morbidity that was similar to those who originally planned to deliver at the 
centre (Philip et al. 1981). 
 
1985 to 1995 
The first successful use of exogenous surfactant for the treatment of RDS was 
described in Japan (Fujiwara et al. 1980), but there was a long delay before the 
findings were translated into a widely accepted clinical therapy. Similarly, 
although antenatal steroids in preterm labour were first shown to be effective in 
reducing the severity of RDS in 1972 (Liggins and Howie 1972), there was a 
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remarkable delay before the use of antenatal steroids became universally ac-
cepted. By the early 1990s, there was overwhelming evidence that the combi-
nation of antenatal steroids and surfactant after birth led to a dramatic reduction 
in the severity of RDS and its consequences. However, this period was also 
characterised by increasing use of the artificial corticosteroid dexamethasone 
for treatment of BPD. It was shown in a randomised trial that in preterm infants 
who were ventilator dependent, a prolonged course of high-dose dexamethasone 
led to faster weaning from ventilator compared with control infants (Cummings 
et al. 1989). Following this study dexamethasone was increasingly adopted by 
neonatologists across the world and little concern was expressed at the time 
about the body of experimental data showing that prolonged courses of high-
dose postnatal steroids could have detrimental effects on the developing brain 
(Yeh et al. 1997, Yeh et al. 1998). 
 
1995 to present 
The 1990s has been the decade of the micro-preemie. Successful treatment of 
infants, with GA of 23 to 25 weeks and BW of 500 to 750 g, has been possible 
through surfactant therapy, more proactive obstetric management, precision 
micromanagement of fluid delivery, sophisticated nutritional management, and 
continued improvement in ventilator management (Wyatt 2010). Awareness of 
early management in the delivery room during the first 60 minutes after birth 
with the beneficial use of prophylactic surfactant and institution of early CPAP 
and its effect on long-term outcome increased (Lussky 1999). In the modern 
era, prolonged MV is often not required and many ELGA infants may be 
supported with CPAP from the first days of life. This has meant that the severe 
and damaging fluctuations in oxygen, carbon oxide, blood pressure, and other 
physiological variables are avoided. The frequent episodes of cardio-respiratory 
collapse and recovery, which were a feature of care in the 1970s and 1980s, are 
now mercifully unusual (Wyatt 2010). In addition, nowadays is widely used the 
Newborn Individualised Developmental Care and Assessment Programme 
introduced by Heidelise Als, which support family-centered, individualised 
developmental care for premature infants while shortening ventilator days and 
improving developmental outcomes of NICU graduates (Als and Gilkerson 
1997). Also, some strategies that have improved long-term outcomes, such as 
caffeine therapy for apnoea of prematurity (Schmidt et al. 2007), have appeared 
in the 2000s. 
Unfortunately, BPD and necrotising enterocolitis (NEC) have remained 
significant clinical problems and there is evidence to suggest that infection may 
have become an increasing problem over the last decade. Antenatal infection is 
increasingly recognised both as an important cause of preterm labour and as a 
causal mechanism underlying a significant proportion of perinatal brain injury. 
Furthermore, impaired growth of both body and head is common over the first 
weeks of life and the problem is exacerbated by frequent episodes of sepsis, 
leading to interruption in enteral and parenteral feeding (Wyatt 2010). Additio-
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nally, there is no consensus in the management of patent ductus arteriosus 
(PDA) (Benitz 2010). 
In general, during all of the abovementioned periods, the changes in the peri-
natal and neonatal care have been followed by controversy about the wisdom of 
providing intensive care for babies born at the limit of viability for that period 
of time. It seems unlikely that the current limits of viability at 22–23 GW will 
change within the next decades. The goal of the current neonatal care is to 
ensure that infants who can benefit from conventional methods of intensive care 
have the best possible chance of intact survival with normal brain development. 
 
 
4.3. Short-term consequences  
of very preterm birth to the individual 
4.3.1 Mortality 
The outcome of VPT infants born 50 years ago was poor. Of the VLBW infants 
admitted to the Colorado General Hospital Premature Infant Centre, only 50% 
survived the first year of life (Lubchenco et al. 1963). Changes in perinatal 
management, including increased antenatal referral, antenatal steroid treatment, 
assisted respiratory support at delivery, and surfactant therapy, have been 
associated with a substantial increase in survival of infants at low GA (Fanaroff 
et al. 2003). Nevertheless, these infants account for one third to one half of all 
perinatal, neonatal, and infant deaths (EURO-PERISTAT Project 2010). 
Although the perinatal mortality rate of VLGA infants has decreased drama-
tically in Estonia since 1992 (Figure 4), 49% of all perinatal deaths in Estonia in 
2011 occurred in infants born below 1500 g of BW (National Institute for 
Health Development 2014). Similarly, Callaghan et al. have shown that 34% of 
all infants dying in the United States of America are VLGA/VLBW infants 
(Callaghan et al. 2006). 
Calculations of mortality up to the first discharge of live-born EPT/VPT in-
fants and/or of EPT/VPT infants admitted to intensive care as denominators are 
most often used. The Neonatal Research Network of the National Institute of 
Child Health and Human Development reported a decline in VLBW infant 
mortality from 26% in 1988 to 16% in 1995–1996 (Hack et al. 1991b, Lemons 
et al. 2001). Similarly, Horbar et al. demonstrated an improvement in the 
mortality rates from 18 to 15% over the years 1991–1999 for infants who 
weighed 500 to 1499 g, but his data did not show any significant change in 
mortality over the last few years of the study, 1997–1999 (Horbar et al. 2002). 
In an another study, mortality rates for VLBW infants were similar to pre-
viously published data for the years 1997–1999 and did not change over time 
thereafter until 2004 (Mohamed et al. 2010). Altogether, it seems that a decline 
in mortality that occurred in the last two decades of the 20th century reached a 
plateau by the end of 1990s. Whether this was attributable to the aggressive 
resuscitation of nonviable infants resulting in a delay in their time of death is 
not yet clear. 
‰ 
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Figure 4. Perinatal mortality rate per 1,000 births of VLGA infants in Estonia (National 
Institute for Health Development 2014) 
 
 
Data on survival often come from specialised neonatal units, with a selection 
bias resulting from different criteria for referral, admission, or treatment. This 
partly explains the better survival rates, especially for the lowest GA, observed 
in some single or multiple centre networks than in population-based studies 
(Evans and Levene 2001). Additionally, mortality risks are inversely related to 
GA. In the population-based studies done since the nineties, the survival for 
ELGA/ELBW infants ranges from 39 to 81% in Europe (Costeloe et al. 2000, 
Vanhaesebrouck et al. 2004, Markestad et al. 2005, Tommiska et al. 2007, 
EXPRESS group 2010, de Waal et al. 2012) and for VLGA/VLBW infants 
from 81 to 88% (Zeitlin et al. 2010, R egger et al. 2012). A study of 10 Euro-
pean regions in 2003 presented the survival rate in VPT infants as ranging from 
79 to 93%, indicating the variability of treatments provided in this population 
(Zeitlin et al. 2008). The respective figures for VLGA/VLBW infants outside of 
Europe are 93% in the United States of America (Bode et al. 2009), 90% in 
Australia (Darlow et al. 2003), and 89% in Japan (Kusuda et al. 2006) whereas 
for ELBW infants, for example, 83% in Japan (Itabashi et al. 2009). 
 
Babies born at the threshold of viability 
Although relatively small in numbers, babies born at or around the limit of 
viability frequently die because of decisions taken shortly after delivery to limit 
intensive care and provide only palliative treatment (Larroque et al. 2004). 
Therefore, they generate a great deal of public interest and a range of often-
polarised options. 
In recent years, the Nuffield Council for Bioethics (Nuffield Council on Bio-
ethics 2006) has reviewed the evidence surrounding the appropriateness of 
treatment for such babies and updated professional guidance from the United 
Kingdom has been published (Wilkinson et al. 2009). In broad terms, these 
ü
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documents suggest that before 23 GW, intervention is not appropriate; at  
23 GW, health professionals should discuss with parents the provision of active 
intervention given the individual circumstances; while at 24 GW, the broad 
expectation would be to proceed with active intervention and intensive care un-
less a baby was in very poor condition at birth. In other countries, such as the 
Netherlands, current policy follows a non-interventionist stance for babies born 
at the limits of viability (Dutch Paediatric Association 2011), whereas in 
contrast, in some parts of the world there appears to be a greater willingness to 
provide full intensive care to babies at 22 GW (Sugiura et al. 2011). 
Seaton et al. assessed the care given to the babies born at the threshold of 
viability over the last 20 years using regional and national data from the former 
Trent health region, United Kingdom. The proportion of babies surviving to 
discharge increased significantly from 1991 to 2010 for those born at 24 and  
25 GW but failed to achieve statistical significance for those at 23 GW. No 
babies born at 22 GW survived (Seaton et al. 2013). The results of the study 
support the view that 23 GW represents the limit of the current technology. 
Nevertheless, management policies could be important for survival of the most 
immature infants. Studies from Sweden and Germany support that proactive 
management promotes survival in infants born at 22 to 25 GW (Hakansson et 
al. 2004, Herber-Jonat et al. 2006). 
 
 
4.3.2. Neonatal morbidity 
Preterm infants are at increased risk of early complications in different organ 
systems (Table 1). Medical problems are especially prevalent among 22–25 GW 
infants, since their extremely immature organs at birth ill-equip them to make 
the transition from intrauterine to extrauterine life (Hakansson et al. 2004, 
Larroque et al. 2004, Lucey et al. 2004). Although neonatal morbidities in pre-
term infants are separate clinical entities, they are also strongly correlated. For 
example, acute lung problems shortly after birth are correlated with circulatory 
problems, brain haemorrhage, and later lung disease. 
 
 
Table 1. Common medical problems in VPT infants (modified from Johansson and 
Cnattigius 2010) 
 
Clinical  
entity Synopsis 
RDS Lung problem developing shortly after birth due to lack of endogenous 
surfactant in the lungs. Surface tension increases in the smallest airways and 
lungs get non-compliant. Treated with instillation of exogenous surfactant in 
the airway. Common reason for MV or CPAP treatment. 
PDA The duct is a blood vessel between the pulmonary artery and the aorta, essential for 
foetal blood circulation. The duct should close after birth but can stay open in 
preterm infants, shunting too much blood to the lungs and leaving too little blood for 
other organs. Can be closed with drugs or surgery. 
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Clinical  
entity Synopsis 
PIVH Bleeding originating in the germinal matrix, a highly vascularised and cellularly 
active tissue beside the brain ventricles. Localised bleedings may not be 
associated with poor outcome, but those resulting in ventriculomegaly and/or 
extending into the brain tissue (PIVH grade 3–4 according to the classification 
by Papile et al. 1978) may have a poor prognosis, and could contribute to 
decisions to withdraw care (end-of-life decisions). 
PVL Damage of brain white matter, related to hypoxia and inflammation. The initial 
insults may usually occur shortly after birth or during a sudden clinical 
deterioration and PVL then develops over the following weeks. Cystic forms of 
PVL (PVL grade 2, particularly PVL grade 3–4 in accordance with data from 
de Vries et al.1992) are strongly associated with later low motor function. 
Infections Very common, due to an immature immune system and much exposure to 
bacteria from the environment (including staff). Bacteria of low virulence and 
fungi are common pathogens. Can usually be treated successfully with anti-
biotics but infection-related mortality is significant. 
NEC Inflammation and necrosis of the bowel, leading to various abdominal symp-
toms. In cases of NEC stage 2 (classification by Bell et al. 1978), treated with 
bowel rest and antibiotics, but surgical bowel resection is commonly performed 
in cases of bowel necrosis and/or perforations (NEC stage 3). 
BPD A more chronic lung problem, related to short GA, RDS, PDA, infection, and 
MV. Months of ventilatory support and supplementary oxygen may be needed 
in severe cases. For VPT infants, BPD is usually defined as a need for supple-
mental oxygen at the postnatal age of 28 days (mild BPD), and/or a need for 
<30% oxygen at 36 weeks of PMA (moderate BPD), and/or a need for ≥30% 
oxygen and/or positive pressure (MV or CPAP) at 36 weeks of PMA or 
discharge, whichever comes first (Jobe et al. 2001). Some, but not all, children 
can be prone to asthma-like problems and have reduced lung function in their 
future life. 
ROP Overgrowth of blood vessels in the immature retina of the eye, related to factors 
such as short GA and oxygen administration. By the international classification 
for ROP (Committee for the Classification of Retinopathy of Prematurity 
1984), the disease is divided into five stages. Low-grade retinopathy (ROP 
stage 1–2), usually resolve without specific therapy but laser treatment may be 
needed in severe forms (ROP stage ≥3). Worst-case scenario includes retinal 
detachment and blindness. 
 
Tables 6 and 7, presented in the section of “Results and discussion”, provide 
neonatal morbidity rates among VLGA/VLBW and ELGA/ELBW infants re-
ported in worldwide population-based or multicentre studies. 
 
 
4.4. Long-term consequences of very preterm birth  
to the individual 
Typical long-term adverse consequences of preterm birth include growth fai-
lure, cerebral palsy (CP), poor cognitive performance (usually intelligence quo-
tient (IQ) <70), and vision and hearing impairments. 
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There is some confusion over the need to correct chronological age for 
prematurity after birth. It is self-evident that proper assessment of growth and 
development over the first year must take into account the level of prematurity, 
and most authorities recommend that the correction has to be continued until  
2 years of age. At this age, after birth at 28 GW, correction produces a 12% 
difference in terms of developmental age. This is an important clinical diffe-
rence compared with the assessment based on chronological age. For more im-
mature children, this correction could be continued longer than this, as the 
difference will be significant until 3 years (24 GW: 11% difference). However, 
by the time a preterm child reaches nursery or school, continuing to make these 
corrections is then irrelevant and makes only clinically insignificant difference 
to developmental scores (Marlow 2004). 
 
4.4.1. Growth 
A number of studies have shown that the majority of VLBW infants in a NICU 
develop growth failure with parameters below the 10th percentile by 36 weeks of 
PMA or by time of discharge from the NICU (Ehrenkranz 2000, Clark et al. 
2003) and many remain small into childhood and adolescence (Hack et al. 
2003). Impaired head growth and subnormal head size are associated with poor 
cognitive function and academic achievement at school (Hack et al. 1991a), 
suggesting a link between postnatal growth and neurodevelopmental potential. 
 
 
4.4.2. Neurosensory outcome 
CP is one of the most common and severe sequelae of VPT birth. VLGA/ 
VLBW infants are between 20 to 80 times more likely to have CP than infants 
born at term (Surveillance of Cerebral Palsy in Europe 2000). Controversy 
exists regarding the trends in prevalence of CP over time. Although some 
studies have indicated an increase with the falling neonatal mortality (Hagberg 
et al. 2001, Vincer et al. 2006), and other studies have documented a stable CP 
rate (Vohr et al. 2005b,  Doyle et al. 2011), a number of more recent studies 
have presented a declining rate of CP in ELBW and VLBW children (Platt et al. 
2007, Groenendaal et al. 2010, Serenius et al. 2013). 
There have been many assessment schemes for neurological outcome 
following preterm birth but the outcome measures reported and definitions of 
disability vary considerably. Key elements of the current CP definitions involve 
the following features: 1) it is a group of disorders of movement and posture 
and of motor function; 2) it is permanent but not unchanging; and 3) it is due to 
a non-progressive interference/lesion/abnormality in the developing/immature 
brain. A European network of health professionals working in the domain of CP 
has agreed on this definition (Surveillance of Cerebral Palsy in Europe 2000), 
which is also in line with a recently proposed international definition (Rosen-
baum et al. 2007). Of the different patterns of CP, spastic diplegia is that most 
typically associated with preterm birth. It is generally thought to be the con-
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A diagnosis of CP does not equate to severe disability nor does not having 
CP mean that no disabilities are present. Therefore, functional outcome mea-
sures are important, as they give a richer picture of child’s abilities (Fawke 
2007). In the 1990s a validated scale – the Gross Motor Function Classification 
System (GMFCS) – became available for assessing bimanual function and gross 
motor function in young children with CP (Palisano et al. 1997). 
Severe problems in sensory deficits are diagnosed during the first years of 
life, whereas again, significant disability from visual or hearing loss is GA 
dependent and rates are moderately consistent across cohorts. Poor visual 
perception in EPT Swedish children born in the early 1990s was five times as 
common as in full-term (FT) controls (21 vs. 4%) (Finnstrom et al. 1998). The 
importance of the contribution of ROP to severe visual loss has become clearer 
in the cohorts born since systematic screening was introduced. However, 
although the increased survival of the more susceptible infants has meant that 
rates and absolute numbers of ROP needing treatment are on the increase, 
gestation specific rates of severe visual impairment over the last decades have 
decreased (Vohr et al. 2005b, Doyle et al. 2011) which may reflect the efficacy 
of ROP screening programmes. 
The rates of CP, blindness, and deafness in population-based and multicentre 
cohorts of VLGA/VLBW and ELGA/ELBW infants are shown in Tables 13 and 
14 in the section of “Results and discussion”. 
 
 
4.4.3. Cognitive and behavioural outcomes 
Despite the perceived importance of CP, the most common outcome disability 
at 2 years of CA is developmental or cognitive impairment, which assumes 
greater significance in the school years (Marlow 2004).  
Standardised developmental assessments are important in the early detection 
of developmental delay in children, determining eligibility for early intervention 
programmes and the evaluation of perinatal and neonatal treatment. The need 
for objective measures has led to the widespread use of standardised IQ tests as 
indicators of outcome. IQ tests are psychometric measures that yield stan-
dardised scores on a normalised distribution (typically mean = 100, standard 
deviation (SD) = 15) and are thus statistically comparable. Although VLGA/ 
VLBW children typically have group mean IQ scores within the normal range 
(±1 SD), these are significantly lower than their FT counterparts (Bode et al. 
2009, Anderson et al. 2010), even for those who are free of severe disability 
(Charkaluk et al. 2010). A meta-analysis of outcome for VLGA/VLBW child-
sequence of injury to the descending motor pathways, in which those fibres 
supplying the lower limb are more prone to bilateral hypoxic-ischaemia, and is 
associated with PVL. Hemiplegia and more complex spastic CP may occur, but 
less commonly and result from more extensive lesions including the cortex.  
In particular, hemiplegia may arise following haemorrhagic periventricular 
infarction, associated with PIVH. The most immature children may have very 
complex motor disability with injury to multiple areas (Fawke 2007). 
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ren aged 5–14 years pooled data from 15 high-quality studies (Bhutta et al. 
2002). Weighted mean differences for individual studies ranged from 7.0 to 
22.7 points, with an aggregate weighted mean difference of 10.9 IQ points (95% 
confidence interval (CI) 9.2–12.5) between VLGA/VLBW children and FT 
controls. Results were unaffected by country, age at assessment, and regional 
versus hospital-based cohorts. The highest weighted mean differences were 
found for studies in which children with severe neurosensory impairments were 
included. The deficit in IQ for ELGA/ELBW children is larger than that for 
VLGA/VLBW cohorts. A regional cohort of ELBW (BW <750 g) children 
scored 13 points lower than FT controls and 6 points lower than low BW 
controls matched for age, sex, and ethnic group (Hack et al. 1994). Follow-up 
data for young ages are now beginning to emerge for cohorts born in the 2000s 
(Bode et al. 2009, Anderson et al. 2010, Munck et al. 2010, Doyle et al. 2011, 
Rattihalli et al. 2011, Serenius et al. 2013) and continue to highlight the cogni-
tive disadvantage in these populations. Within-group analyses for VPT children 
have shown a correlation between IQ and GA. Bhutta et al. identified a linear 
relationship between GA and IQ from 25 to 40 GW (Bhutta et al. 2002). 
While there is no criterion standard for determining developmental delay 
(Johnson and Marlow 2006, Aylward 2009), the Bayley Scales of Infant 
Development (BSID) (Bayley 1969) and its revisions – BSID-II and BSID-III – 
(Bayley 1993, Bayley 2006) are the most widely reported measures. BSID-II 
has been used in many studies to determine rates of developmental delay in 
VPT children and perinatal factors associated with poor outcome (Wood et al. 
2000, Vohr et al. 2005b, De Groote et al. 2007, Wilson-Costello et al. 2007, 
Munck et al. 2010). The primary scales from the BSID and BSID-II are the 
Mental Developmental Index (MDI) and the Psychomotor Developmental Index 
(PDI). In brief, the MDI evaluates early cognitive and language development, 
while the PDI evaluates early fine and gross motor development. The broad 
natures of both the MDI and PDI are the main limitations of the BSID and 
BSID-II. For example, low MDI scores may reflect a specific delay in commu-
nication skills, cognitive abilities, or both. BSID-III attempts to address this 
limitation by refining the measure to include separate composite scores for 
cognitive, language, and motor domains. In addition, scale scores can be calcu-
lated to assess receptive communication, expressive communication, and fine 
and gross motor development. Thus, the structure of the new BSID-III has the 
potential to provide more clinically useful information relating to early develop-
ment, improving the capacity to discriminate specific developmental problems 
and helping to target early intervention programmes to more specific areas of 
weakness. The majority of studies have demonstrated that EPT and VPT infants 
obtain lower scores on the BSID–II MDI, as well as on PDI, when compared 
with a FT control group at 24 months of age (Munck et al. 2010, Voigt et al. 
2012). To date, the first published studies have used the BSID-III (Bode et al. 
2009, Doyle et al. 2011, Janssen et al. 2011, Serenius et al. 2013), and the 
original enthusiasm for this measure may have waned, with many clinicians 
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suggesting that it overestimates development and, as such, underestimates delay 
(Anderson et al. 2010, Moore et al. 2012). 
Behavioural and other psychological outcomes seem to be equally proble-
matic (Marlow 2004). The VPT child is at increased risk for subclinical beha-
vioural problems and can most often be described as inattentive, shy or with-
drawn, and with poor social skills. VPT children are more likely to have 
psychiatric disorders, of which attention deficit and hyperactivity disorders are 
the primary abnormal outcome. There is also some evidence of increased risk 
for Autistic Spectrum Disorders in VPT children (Johnson 2007, Schendel and 
Bhasin 2008). 
Neurodevelopmental impairment (NDI) is a well-known definition for 
describing combined outcome for VPT infants. Usually NDI is defined as the 
presence of CP, delayed mental development (MDI >2 SD below the mean), 
severe hearing impairment, and/or severe visual impairment (Bode et al. 2009, 
Munck et al. 2010). 
 
4.4.4. Respiratory outcome 
Chronic respiratory diseases are a common complication of preterm birth, 
particularly among very immature infants or those suffering from BPD (Jobe 
and Bancalari 2001). Lung injury and the subsequent maladaptive repair process 
that leads to the development of chronic lung problems are complex, with 
numerous factors (for example, degree of immaturity, BPD, inflammatory me-
diators, atypical pathogens, recurrent viral infections) interacting to determine 
outcome (Kwinta and Pietrzyk 2010). Preterm infants with BPD may require 
supplementary oxygen for many months or even years (Greenough et al. 2002), 
although few remain oxygen dependent beyond 2 years of age (Greenough et al. 
2006). Infants requiring supplementary oxygen at home have the most severe 
lung disease, as evidenced by their need for hospital readmission in the first two 
years after birth being twice that of those with BPD who are not oxygen 
dependent (Greenough et al. 2002). 
The major respiratory problem in infancy and early childhood is respiratory 
exacerbations caused by infection, particularly viral ones (Kwinta and Pietrzyk 
2010). While acute respiratory morbidity in infants born FT is relatively well 
studied, in contrast, data for VPT infants, especially during post-surfactant era, 
are scarce. Previous studies have shown that premature infants are more 
susceptible to acute respiratory infections (RI) than FT infants, having more 
wheezing episodes and hospital readmissions due to respiratory problems in the 
first two years of life (Lamarche-Vadel et al. 2004, Smith et al. 2004, Bhandari 
and Panitch 2006, Holditch-Davis et al. 2008, Kwinta and Pietrzyk 2010, 
Pramana et al. 2011). Moreover, they are more likely to die during infancy from 
acute lower respiratory tract infections than other infants (Holman et al. 2003). 
Hospitalisation rates decline after the 2nd year of life and are infrequent in 14-
year-old children who had been born preterm regardless of their BPD status 
(Doyle et al. 2001). 
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The chronic respiratory symptoms become mild in school-age children 
(Filippone et al. 2009). However, for some preterm infants, particularly those 
with BPD, obstructive lung disease persists into adulthood (Northway et al. 
1990). Prematurity is associated with an increased risk of asthma from child-
hood to adulthood. In a population-based register study in Finland, a substan-
tially increased risk of asthma was observed for premature children compared 
with the risk for FT and normal-weight children, whereas two thirds of the cases 
were diagnosed before the age of 3 years (Metsala et al. 2008). The association 
between prematurity and asthma has been explained, firstly, by the fact that 
prematurity causes reduced lung growth and reduced airway calibre, which may 
increase wheezing symptoms during RI and in turn increase asthma diagnose, 
and secondly, because prematurity may predispose the child to respiratory tract 
infections, which would further strengthen these associations. 
 
 
4.4.5. Adult outcome  
With regard to preterm birth and outcomes in adulthood, we need to consider 
that modern neonatal intensive care has a short history. Consequently, very little 
is known about health in adult life for the growing number of children who have 
survived VPT and EPT birth since the 1990s. Follow-up studies of adults born 
VPT predominantly include individuals born during the late 1970s and early 
1980s (Saigal et al. 2006, Lindstrom et al. 2007, Moster et al. 2008). The results 
from cohort studies of EPT infants for which there was a FT or normal BW 
group for comparison have shown that in early adulthood as a group, survivors 
of extreme prematurity have higher rates of many adverse health outcomes 
compared to FT controls: for example, a higher risk of neurological impair-
ments, low vision, epilepsy, hearing loss (Saigal et al. 2006, Moster et al. 2008), 
poor education and employment (Lindstrom et al. 2007), and disorders of 
psychological development, behaviour, and emotion (Moster et al. 2008). Even 
among those who were recorded as not having medical disabilities, the 
proportions of people who achieved higher education, held well-paying jobs, 
established a family, had biological children, and did not receive social security 
benefits were lower (Moster et al. 2008). 
 
 
4.5. Consequences of very preterm birth on  
families and to the society 
Clearly, from all studies, prematurity and its associated sequelae have an enor-
mous negative psychological and emotional effect on the family (Cronin et al. 
1995, Singer et al. 1999, Taylor et al. 2001, Moore et al. 2006). The effect of 
psychological and emotional distress was greatest for VLBW high-risk infants 
in the first month of life and persisted during the first two years of life. By the 
age of 3 years, parenting stress remained greater for VPT infants than for 
normal BW infants (Singer et al. 1999). The effect seems to vary according to 
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medical risk factors, developmental outcome, family environment and income, 
parental education, and child’s age at reporting (Cronin et al. 1995, Singer et al. 
1999, Taylor et al. 2001, Moore et al. 2006). 
The financial burden of prematurity to the society is significant. Several 
studies have demonstrated that preterm births contribute disproportionately to 
overall delivery costs, accounting for a small percentage of discharges, but 
approximately half of all costs (Schmitt et al. 2006, Russell et al. 2007). One 
example appears in a study (Russell et al. 2007) where 8% of all births included 
a diagnosis of preterm birth or low BW, yet these accounted for 47% of the total 
costs. Thus, the costs of the initial hospitalisation in VPT infants are high, and 
the costs along with the length of stay increase with decreasing GA or BW 
(Phibbs and Schmitt 2006). In addition to the long initial hospitalisation, the 
need for hospital inpatient and outpatient care remains substantial during the 
first years of life in VPT children (Gray et al. 2006). 
There are few studies on the use of healthcare resources reaching beyond the 
first year of life and beyond childhood in the preterm population. For example, 
Leijon et al. have shown that there were no significant differences in visits to a 
general practitioner between VPT infants and FT controls during the first four 
years of life (Leijon et al. 2003). However, during the first year of life, 67% of 
VPT infants had visits to specialists, versus 26% of FT controls. Between 1 to  
4 years of age, the respective figures were 74 vs. 45% (Leijon et al. 2003). In a 
Finnish study, the healthcare costs during the fifth year of life in VPT children 
with morbidities were 4.4-fold and in those without morbidities 1.4-fold com-
pared with those of FT control subjects (Korvenranta et al. 2010). In contrast, 
Saigal et al. showed that the use of health-care resources in ELBW infants in 
young adulthood in terms of hospitalisations, surgical procedures, visits to 
specialists, or in the use of rehabilitative services were not significantly diffe-
rent compared to FT controls (Saigal et al. 2007). 
Assessing the costs of the care of VPT infants in terms of quality-adjusted 
life years (QALY) enables to describe the cost-effectiveness of care. The cost 
per QALY in preterm children has been evaluated by Cutler and Meara (Cutler 
and Meara 1999). This study was based on estimations from different studies 
and suggested a cost per QALY of $6,101 for those born with BW below 1000 g 
and $1,290 for those weighing 10001500 g at birth, assuming that the children 
reach 50 years of age. Although there is no absolute cut-off, in the Unites States 
tends to be general consensus that treatments with a cost-effectiveness ratio of 
$50,000 to $100,000 per year of life gained are acceptable (Talmor et al. 2006). 
Consequently, the study by Cutler and Mara indicated that the benefit of treat-
ment of prematurity was so large that it dwarfed all the uncertainties inherent in 
the data (Cutler and Meara 1999). 
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4.6. Factors impacting on outcomes  
in very preterm infants 
Factors contributing to the outcome of VPT infants include the characteristics 
presented in Table 2. 
 
 
 
4.6.1. Intrauterine environment 
Inflammatory mechanisms are known to be associated with preterm birth and 
neonatal morbidities. Proinflammatory cytokines in amniotic fluid and in foetal 
blood appear to increase the risk of neonatal brain injury and adverse long-term 
outcome. Associations have been reported between antenatal infection, a foetal 
inflammatory response, vasculitis, PPROM, white matter damage, and long-
term disability (Dammann et al. 2001, Dammann et al. 2002, Yoon et al. 2003, 
Beaino et al. 2010). Two maternal complications associated with inflammation 
and infection, chorioamnionitis and PPROM, are associated with the develop-
ment of PVL. In a report examining the association between histological chorio-
amnionitis and PVL, severe inflammation in the umbilical cord was observed in 
53% of infants with PVL and 32% without PVL (p <0.05) (Wharton et al. 
2004). In turn, PVL is strongly associated with an increased rate of CP and 
associated morbidities (Perlman 1998). In a systematic review and meta-ana-
lysis with the aim to find associations between chorioamnionitis and ROP in 
preterm infants, unadjusted analyses showed that chorioamnionitis was signifi-
Table 2. Spectrum of factors contributing to outcomes of VPT infants (modified from 
Vohr 2010) 
 Characteristics 
Intrauterine environment Maternal infection and hypertension, drug 
exposure, smoking, and multiple gestation 
Perinatal and neonatal 
interventions 
Delivery in tertiary centres, timing of delivery 
and use of antibiotics, administration of ante-
natal corticosteroids, delivery by caesarean 
section, surfactant replacement therapy, use of 
MV or non-invasive respiratory support and 
oxygen supplementation beyond stabilisation, 
management of PDA, postnatal corticosteroids, 
nutrition and growth 
Neonatal characteristics and 
morbidities 
Extreme prematurity, gender, PIVH, PVL, 
BPD, NEC, sepsis, ROP 
Post-discharge environment Maternal education, family income, health 
insurance, early intervention services 
Post-discharge healthcare needs BPD, anaemia, osteopenia, hernias, recurrent 
hospitalisation 
Comorbidities Congenital anomalies, CP, vision and hearing 
impairment 
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cantly associated with ROP as well as with severe ROP. However, the associa-
tion disappeared on analysis of studies adjusting for GA (Mitra et al. 2014). 
Also the clinical research on relationships between chorioamnionitis and RDS 
and BPD remains unsettled (Jobe 2011). 
Few studies have addressed antenatal risk factors for cognitive develop-
mental impairment. Helderman et al. have shown in a cohort of ELGA infants 
surviving at 2 years of CA that maternal obesity and one placental finding  
thrombosis of foetal stem vessels  were associated with impaired early cogni-
tive function (Helderman et al. 2012). 
Multiple pregnancies are often complicated by increased maternal compli-
cations, preterm delivery, perinatal complications, intrauterine growth rest-
riction (Donovan et al. 1998), and increased rates of adverse neurodevelop-
mental outcomes (Pharoah 2002). 
 
 
4.6.2. Perinatal and neonatal interventions 
Delivery in tertiary centres and the effect of regionalisation 
Many studies have concluded that the risk of neonatal death is lower when a 
VPT birth occurs in a maternity unit with an onsite NICU (Ozminkowski et al. 
1988, Lasswell et al. 2010). This result is attributed to differences in the quality 
of care, the concentration of technical expertise, and coordination between 
obstetrical and neonatal teams in tertiary level perinatal units as well as to the 
deleterious effects of transporting immature newborns in an ambulance after 
birth to an intensive care unit (Smith et al. 1990). Even in healthcare with well 
organised transport systems, the mortality and morbidity of immature inborn 
infants are lower than those of outborn infants who are transported after 
delivery (Palmer et al. 2005, Rautava et al. 2007, Mohamed and Aly 2010), and 
decrease further at hospitals with higher volumes of patients and higher levels 
of care (Phibbs et al. 2007). Although Watson and his colleagues did not find 
evidence for an association between inter-facility transport and PIVH or 
mortality among VLBW infants after accounting for potential confounders, 
there was an independent association between the overall clinical status of the 
infant, PIVH, and inborn vs. outborn status (Watson et al. 2013). 
Two meta-analyses have summarised the results of the literature on the 
effects of the regionalisation. Ozminkowski et al. (Ozminkowski et al. 1988) 
meta-analysis included 19 non-randomised studies, and the results showed 
strong preferences for inborn status, especially for infants weighing between 
10012000 g. Lasswell (Lasswell et al. 2010) included 41 studies on VPT 
infants. Adjusted odds ratio (OR) of death for VPT infants was 1.55 (95% CI 
1.211.98) if born outside of tertiary level unit. No change over time was found 
according to year of publication. Some studies have found that the benefits of 
delivering in tertiary level structures are greatest for EPT infants (Lee et al. 
2003, Johansson et al. 2004), but this result has not been found elsewhere 
(Empana et al. 2003). Concerning the long-term outcome, Rautava et al. 
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(Rautava et al. 2013) have shown that long-term health outcomes for EPT 
infants are better if they receive their whole initial neonatal care in tertiary units. 
National recommendations about delivery of VPT infants in tertiary centres 
exist in many countries. The American Academy of Paediatrics recommends 
that deliveries at <32 GW take place in specialised units (Stark 2004) and most 
European countries have passed laws or issued recommendations based on this 
premise (Zeitlin et al. 2004). In Estonia, there is a general consensus of profes-
sional societies to regionalise the births before 34 GW. 
 
Timing of delivery and use of antibiotics 
Preterm delivery can be delayed by using tocolytic drugs and antibiotics in the 
case of PPROM. Tocolysis prolongs gestation and allows other antenatal inter-
ventions, such as antenatal steroids and centralisation of care, to be fully imple-
mented. In Sweden, tocolysis was associated with both significantly increased 
survival and a doubled chance of one-year survival without severe neonatal 
morbidity (Fellman et al. 2009, Haas et al. 2012). Magnesium sulphate given to 
women at risk of imminent preterm birth has been shown to reduce the in-
cidence of CP (Doyle et al. 2009). Progesterone supplementation may delay 
preterm birth in women with a history of previous preterm delivery and those 
with a short cervix (Rode et al. 2009). 
PPROM is responsible for approximately one third of all preterm births 
(Stringer et al. 2004). During management of PPROM, physicians must balance 
the risk of RDS and other sequelae of premature delivery with the risks of preg-
nancy prolongation, such as neonatal sepsis and cord accidents (Medina and 
Hill 2006). Therefore antibiotic therapy for women in PPROM at 34 GW or less 
is a routine practice to delay labour and reduce neonatal morbidity. Meta-ana-
lyses support positive effect of antibiotic therapy in some short-term outcomes 
(Hutzal et al. 2008, Kenyon et al. 2010) such as reduction in chorioamnionitis 
and in infants' morbidity markers (neonatal infection, use of surfactant, oxygen 
therapy, and abnormal cerebral ultrasound scan prior to discharge from 
hospital). However, evidence is not conclusive for long-term outcomes. 
 
Administration of antenatal corticosteroids 
Significant evidence has accumulated in clinical trials of the beneficial effects 
of antenatal steroid administration in improving survival and decreasing the 
incidence of RDS, PIVH, PVL, NEC, and early systemic infections among 
preterm infants (Wright et al. 1995, Roberts and Dalziel 2006, Carlo et al. 
2011). Prenatal steroids given to women with anticipated preterm delivery 
reduce the risk of neonatal death (relative risk, 0.55; 95% CI 0.430.72; number 
needed to treat = 9), and the use of a single course of antenatal steroids does not 
appear to be associated with any significant maternal or short-term foetal 
adverse effects (Roberts and Dalziel 2006). Antenatal corticosteroid therapy is 
recommended in all pregnancies with threatened preterm labour between 24 and 
34 GW by the American Congress of Obstetricians and Gynaecologists Com-
mittee (ACOG Committee on Obstetric Practice 2011). Effects of multiple 
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courses of steroids on foetal growth have raised concerns about recommending 
more than a single additional rescue course (Peltoniemi et al. 2011). However, 
further information is required concerning optimal dose to delivery interval, 
optimal corticosteroid to use, effects in multiple pregnancies, and to confirm the 
long-term effects into adulthood (Roberts and Dalziel 2006). 
In multivariate analyses, antenatal steroids are consistently the only antenatal 
intervention contributing to the decreased rates of CP (Vohr et al. 2005b) and 
NDI (Vohr et al. 2000, Carlo et. al. 2011). 
 
Delivery by caesarean section 
The optimal mode of delivery for women thought to be in labour and at high-
risk of delivering a small baby is controversial. No randomised controlled trial 
has compared route of delivery in preterm infants, but observational studies 
support an improved outcome with the use of caesarean delivery. In a review of 
linked birth and infant death certificates from 2000 to 2003, Malloy reports a 
significant reduction in neonatal mortality for infants delivered by caesarean at 
22 to 25 GW (Malloy 2008). Caesarean section had been proposed in preterm 
labour in order to reduce the infant's morbidity and mortality, but is associated 
with maternal morbidity (Grant and Glazener 2001). However, a study from 
Europe showed a large variability of caesarean section rates (from 29 to 84%) 
for infants born between 28 and 31 GW without correlation to detected morbi-
dity and mortality, with the exception of pregnancies with hypertension and 
foetal growth restriction (Zeitlin et al. 2010b). 
 
Surfactant replacement therapy 
Surfactant replacement therapy has reduced mortality and several aspects of 
morbidity in newborns with RDS and is nowadays a standard treatment in VPT 
infants with RDS (Sweet et al. 2013). Surfactant replacement therapy is crucial 
in the management of RDS, but the best preparation, optimal dose and timing 
(prophylactic vs. selective) of administration at different gestations are not 
always clear (Sweet et al. 2013). For many years, surfactant prophylaxis for 
EPT infants was considered to offer the best chance of survival (Soll and Mor-
ley 2001). More recent clinical trials show that with a policy of early initiation 
of CPAP and selective surfactant administration (rather than routine prophyla-
xis) babies may do better with reduced rates of death or chronic lung disease in 
the CPAP group (Rojas-Reyes et al. 2012). MV can be avoided by using the 
“INSURE” (INtubate – SURfactant – Extubate to CPAP) technique and this 
method has been shown in randomised trials to reduce the need for MV and 
subsequent BPD (Stevens et al. 2007). 
 
Use of MV or non-invasive respiratory support and oxygen 
supplementation beyond stabilisation 
MV is associated with significant short- and long-term morbidity in VPT infants 
and should be used to support babies when other methods of respiratory support 
have failed (Sweet et al. 2013). Nowadays most of the evidence suggests that 
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non-invasive respiratory support is a viable alternative to MV in many preterm 
infants. Non-invasive respiratory support can be defined as any form of 
respiratory support that is not delivered via an endotracheal tube. It includes 
CPAP, various types of ventilation provided through soft nasal prongs or masks 
which are collectively called “nasal intermittent positive pressure ventilation”, 
and humidified oxygen delivered by high-flow nasal cannulae (Bancalari and 
Claure 2013). Consequently, avoidance of MV by means of early CPAP with or 
without surfactant administration may still be the most effective way to reduce 
the risk of lung injury (Sweet et al. 2013). There are clear links between MV 
through an endotracheal tube and subsequent development of BPD and neuro-
developmental sequelae (Philip 2012). Although the degree of immaturity is by 
far the most important risk factor for ROP, prolonged oxygen dependency and a 
longer duration of MV are also found to be important risk factors for severe 
ROP (EXPRESS Group 2010, Chen et al. 2011). Strict monitoring and admi-
nistration of oxygen is crucial for decreasing the incidence of ROP. Presently, 
studies are being performed to determine the optimal level of oxygen supple-
mentation to further decrease the risk (Sears et al. 2009). Excess supplemental 
oxygen exposure is to a lesser extent also linked with development of BPD 
(Saugstad 2007, Chen et al. 2011). 
 
Management of PDA 
The failure of ductus closure can induce hemodynamic effects if blood is 
shunted from the systemic circulation to the pulmonary circulation. The resul-
ting pulmonary over-perfusion increases the risk of BPD and the systemic 
hypoperfusion may increase the risk of NEC, renal failure, and PIVH/PVL 
(Chiruvolu and Jaleel 2009). Although there are several papers addressing im-
portant issues on prevention (restricted vs. liberal water intake, pharmacological 
closure) (Bell and Acarregui 2008, Fowlie et al. 2010) and treatment of PDA 
(Shah and Ohlsson 2006, Malviya et al. 2008), a review in 2010 concludes that 
trials using current management of PDA are not justified (Benitz 2010). 
Additionally, despite two multicentre trials having shown a beneficial effect of 
prophylactic indomethacin, no differences in CP and NDI at 24 years of age 
were obtained (Ment et al. 1994, Ment et al. 2000, Schmidt et al. 2001). There is 
an observational association between surgical ligation and an increased risk of 
long-term adverse effects; however, it is not clear if this is a direct result of 
surgery or due to complications incurred while waiting for it (Malviya et al. 
2008). 
 
Postnatal steroids 
Corticosteroids have powerful anti-inflammatory effects. After initial reports 
indicated the beneficial effects of postnatal steroids for ventilator-dependent 
infants, administration to VPT infants became almost universal for BPD (Cum-
mings et al. 1989). However, it is unclear whether any beneficial effects out-
weigh the adverse effects of these drugs. The reports of Yeh et al. (Yeh et al. 
1997, Yeh et al. 1998) first established a link between postnatal steroid admi-
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nistration and adverse motor outcomes. In addition, adverse effects on cognitive 
function at school age have also been reported (Yeh et al. 2004). The American 
Academy of Paediatrics (Watterberg 2010) has recommended against the 
routine use of systemic steroids to treat or prevent BPD, and stated that eviden-
ce is insufficient to recommend both low dose dexamethasone or hydrocorti-
sone and invite clinicians to make individualised decisions in conjunction with 
the infant's parents. Recent reviews continue to discourage the use of hydro-
cortisone in chronically ventilator-dependent infants with established or 
evolving BPD (Doyle et al. 2010). 
 
Nutrition and growth 
Maternal breast milk remains the choice of enteral nutrition for preterm infants 
according to observational studies and meta-analyses, whereas breast milk is 
beneficial for VPT infants for the same reasons as for FT infants (Callen and 
Pinelli 2005, Lucas 2005). Additionally, breast milk may confer protection 
against NEC (Callen and Pinelli 2005) and contribute to neurological develop-
ment (Lucas 2005). Furthermore, breastfeeding represents an opportunity to 
involve mothers in infant care during hospitalisation and to encourage mother-
child bonding (Flacking et al. 2006). There are no data from randomised 
controlled trials to determine whether feeding preterm infants with nutrient-
enriched formula milk versus human breast milk affects growth and develop-
ment as it seems very difficult and probably unethical to randomise infants to 
receive maternal versus formula milk. (Henderson et al. 2007). The limited 
available data suggest that feeding preterm infants following hospital discharge 
with multinutrient fortified breast milk compared with unfortified breast milk 
increases growth rates during infancy (McCormick et al. 2010). 
Several recent reports have indicated that poor postnatal weight gain (Fortes 
Filho et al. 2009, EXPRESS Group 2010) and low serum insulin-like growth 
factor 1 levels (Hellstrom et al. 2003) are predictors for neonatal morbidities, 
for example, for ROP. 
 
 
4.6.3. Neonatal characteristics and morbidities 
Extreme prematurity and gender 
Mortality in VPT infants is inversely related to GA. Numerous studies show 
that low GA and BW (Tommiska et al. 2001; Vanhaesebrouck et al. 2004, 
Evans et al. 2007; Itabashi et al. 2009) are risk factors for perinatal and neonatal 
deaths in VPT infants; whereas the more growth restricted the infant, the greater 
is the risk of mortality (Evans et al. 2007). Similar to mortality, morbidity risks 
are inversely related to GA. Compared to FT infants, VPT commonly suffer 
from multiple and interacting morbidities (listed in Table 1) whereas medical 
problems are especially prevalent among infants born at 2225 GW. The rates 
of mortality and morbidity in population-based and multicentre cohorts of 
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ELGA/ELBW infants are shown in Tables 7 and 14 in the section of “Results 
and discussion”. 
Premature males are at a significantly increased risk of neonatal death, in-
hospital morbidity (Stevenson et al. 2000), and poor neurodevelopmental out-
comes (Vohr et al. 2000). The neonatal and neurodevelopmental outcomes at 
1822 months' CA were evaluated in a large cohort of ELBW boys and girls 
born in 1997 to 2000 (Hintz et al. 2006). Girls were more likely to survive 
(67%) than boys (58%) and boys were more likely to have BPD, PIVH grade 
34, and ROP stage ≥3. Additionally, boys were significantly more likely to 
have a MDI 70 (42 vs. 27% for girls), CP, low PDI, and NDI. 
 
PIVH and PVL 
Brain injury that occurs in association with severe PIVH grade 34, PVL, 
ventriculomegaly, or white matter injury has consistently been demonstrated to 
be associated with poor developmental and neuromotor outcomes. In a number 
of large cohort studies of VPT infants PIVH grade 34 and PVL have been 
independently associated with NDI at 1822 months of age after adjusting for 
known confounders, and, in fact, the majority of neonates with these findings do 
develop neurological sequelae (Vohr et al. 2000). In the international multi-
centre outcome study of ELBW infants reported by Schmidt et al. (Schmidt et 
al. 2003), among infants with brain injury (defined as the presence of echodense 
intraparenchymal lesions, PVL, porencephalic cysts, ventriculomegaly with or 
without PIVH, and PIVH grade 34 on neonatal ultrasound scanning) 42% had 
a MDI 70 compared with 23% of infants who had no evidence of brain injury. 
Infants with brain injury also had increased rates of CP (36 vs. 7%) compared to 
infants with no brain injury. 
Beaino et al. assessed in a prognostic manner, the associations between a 
detailed set of obstetric and neonatal risk factors and CP in a large population-
based cohort of VPT infants and found that cerebral lesions on neonatal ultra-
sound screening were the most important predictors of CP in VPT infants. In 
particular, after adjustment for other factors, the odds of developing CP were 
increased 30-fold in infants with cystic PVL or intraparenchymal haemorrhage 
(Beaino et al. 2010). 
 
BPD 
Northway et al. (Northway et al. 1990) have re-evaluated pulmonary function in 
their original cohort of infants with severe BPD reported in 1967. These young 
adults still exhibited some evidence of pulmonary dysfunction comprising 
airway obstruction and hyperactivity as well as hyperinflation. Nowadays, the 
outcome of infants with BPD has improved, in part because of better manage-
ment, but mainly because of the milder presentation of the disease. Neverthe-
less, pulmonary function studies of infants with a history of BPD indicate that 
pulmonary function may be impaired for many years even though the infants 
may be asymptomatic (Jobe 2011). 
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Infants with BPD also exhibit impaired growth curves and have more neuro-
developmental sequelae when compared with similar control groups. Schmidt et 
al. (Schmidt et al. 2003) reported the rate of low cognitive function at 18 
months of CA in ELBW children with BPD. Children with BPD were more 
likely to have an MDI 70 (36 vs. 19%), CP (17 vs. 9.3%), and deafness (3.5 
vs. 1.4%) compared with ELBW children with no BPD. 
 
NEC 
In a multicentre study of ELBW infants, increased severity of NEC was as-
sociated with higher mortality and longer duration of hospitalisation. At 1822 
months of CA, infants who had surgically managed NEC had higher rates of 
MDI <70, PDI <70, and NDI (44, 37, and 57%, respectively) than those ma-
naged medically (37, 25, and 44%), or those without NEC (31, 19, and 40%) 
(Hintz et al. 2005). Regression analyses showed that surgical NEC was 
associated with significantly larger proportion of children with MDI <70, PDI 
<70, NDI, and growth failure at 2 years of CA. 
 
Sepsis 
Sepsis is not only a major cause of death after the first week of life but it also 
prolongs the duration of MV, disrupts nutrition and growth, triggers other 
neonatal co-morbidities such as PDA, BPD, and ROP (Stoll et al. 2004, Liu et 
al. 2005), and increases the risk for later disability. Stoll et al. found that com-
pared with uninfected infants, those with neonatal infection were significantly 
more likely to have adverse neurodevelopmental outcome at follow-up, in-
cluding CP (range of significant ORs, 1.41.7) (Stoll et al. 2004). A report from 
the United Kingdom noted a 4-fold increase in CP among VLBW infants with a 
history of neonatal sepsis compared with infants with no history of neonatal 
infection (Wheater and Rennie 2000). 
 
ROP 
ROP is one of the significant predictors of poor neurodevelopmental outcome. 
The children involved in the CRYO-ROP (Cryotherapy for Retinopathy of 
Prematurity) multicentre study were initially evaluated at 5.5 years. Rates of 
severe disability increased from 3.7% for those children with no ROP to 19.7% 
for those with threshold ROP (Msall et al. 2000). A subgroup of the children 
with threshold ROP was re-evaluated at 8 years of age. Overall, 70% of children 
with an unfavourable vision outcome and 56% with a favourable outcome had a 
neurodevelopmental, behavioural, or learning disorder (Msall et al. 2004). 
Although rates of NDI were high for both groups of children with a history of 
threshold ROP, it was the group of children with vision impairment at 8 years 
who were more likely to have multiple morbidities. 
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4.6.4. Post-discharge environment,  
post-discharge healthcare needs, and comorbidities 
When examining predictors of outcomes, environmental factors, including 
maternal education, race, family income, health insurance, and exposure in 
intervention services, have all been shown to have an impact on cognitive out-
come (Vohr 2010). Although a disadvantaged environment is well known to be 
associated with higher rates of cognitive impairment, children born VPT from 
high socioeconomic backgrounds still have, approximately, a 10-point reduction 
in IQ compared to FT controls (Hack et al. 1995). 
The benefits of an enriched home environment are clear. Data from the 
Infant Health and Development Programme demonstrate that infants who 
receive early intervention have developmental scores significantly higher than 
infants in the control group who received standard care. Early childhood 
development programmes have been associated with reductions in grade reten-
tion and placement in special education (Stewart 2008). 
After discharge, VPT infants are at increased risk of continued complex 
medical morbidities, including BPD, requiring home oxygen or ventilator 
management, gastrointestinal reflux disease, poor feeding, and growth failure. 
Special healthcare needs, which present themselves in the NICU, may persist 
and increase with increasing age. Hack et al. (Hack et al. 2005a) evaluated a 
cohort of ELBW infants born in 19921995 at 8 years of age. Compared to age- 
and gender-matched controls, ELBW infants had more asthma requiring therapy 
(21 vs. 9%), took more regular prescribed medications (37 vs. 19%), were 
hospitalised more often after the neonatal period (23 vs. 6%), received some 
type of specialised services such as physical or occupational therapy (31 vs. 
3%), and had an individualised education plan (39 vs. 9%). Therefore, VPT 
infants should have a comprehensive evaluation by a multidisciplinary team to 
establish an informed clinical opinion to determine, first, their health and 
development, and second, whether early intervention services are needed 
(British Association of Perinatal Medicine 2008). 
Most follow-up studies exclude infants with major congenital anomalies 
from their study sample. The neurodevelopmental outcomes of VPT infants 
with anomalies are needed, however, both for counselling parents regarding 
outcomes and for facilitation of appropriate support and intervention services. 
The cognitive outcomes of ELBW infants with major anomalies were evaluated 
in a large cohort of ELBW infants cared for in the National Institute of Child 
Health and Human Development Neonatal Network centres (Walden et al. 
2007). At the 1822 month follow-up, a greater percentage of children in the 
anomaly group had MDI scores <70 (57 vs. 31%), PDI scores <70 (48 vs. 20%), 
moderate to severe CP (18 vs. 6%), and NDI (65 vs. 37%). Regression models 
adjusting for confounders indicated that infants with severe anomalies had 
nearly twice the risk of having MDI or PDI scores 70 compared to ELBW 
infants without anomalies (Walden et al. 2007). 
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Preterm infants with CP have associated cognitive impairment. A cohort of 
ELBW infants participating in the National Institute of Child Health and Human 
Development Neonatal Network was categorised by neurological status and 
type of CP at 1824 months' CA (Vohr et al. 2005a). There was a significant 
amount of IQ score variability by type of CP: 96% of children with quadriplegia 
had MDI <70, whereas the respective figure for children with hemiplegia was 
41%, with diplegia 69%, and with hypotonic CP 84%. 
 
 
4.7. Evaluation and improvement of the quality  
of perinatal and neonatal intensive care for  
very preterm infants 
Neonatal intensive care is expensive. The cost is measured not only in financial 
terms, but also by the burden of illness caused by the inability to fund alterna-
tive healthcare programmes that have to be foregone to finance neonatal inten-
sive care. For those responsible within the healthcare system, including those 
who treat the babies directly, it is obviously vital to evaluate neonatal intensive 
care for VPT infants thoroughly. 
 
Effectiveness, efficiency, and availability of neonatal intensive care 
Sinclair et al. (Sinclair et al. 1981), in their landmark paper on the evaluation of 
neonatal intensive care programmes, wrote in 1981: “… the overall effective-
ness of these programmes has not been tested experimentally…” and “We 
conclude that neonatal intensive care programmes require further evaluation 
with rigorous scientific methods”. In the 30 years since their comments, the 
need for evaluation of neonatal intensive care programmes has not diminished; 
indeed, it has increased because intensive care has been offered to more EPT at 
considerable cost to health budgets (Doyle 2006). 
Sinclair et al. (Sinclair et al. 1981) described four steps required to evaluate 
neonatal intensive care programmes: efficacy, effectiveness, efficiency, and 
availability. Efficacy asks whether a program works under ideal conditions, in 
contrast with effectiveness, which investigates whether a programme works 
under normal or “field” conditions. Efficiency assesses whether the programme 
is worth implementing, and availability examines whether the programme is 
reaching those who need it. 
Despite the lack of randomised controlled trials of complete neonatal inten-
sive care programmes, Sinclair et al. (Sinclair et al. 1981) indicated that sub-
experimental studies, such as cohort studies, had provided some data on effecti-
veness. Ideally, effectiveness, efficiency, and availability all should be 
evaluated within the geographically defined regions that are served by the pro-
gramme (Doyle 2006). 
 
 
40 
Data sources for evaluation and improvement: why, when, and how should 
neonatal outcomes be reported? 
Regular follow-up and assessment are important for identifying the particular 
needs of any individual VPT child. However, there are additionally two major 
reasons for collecting perinatal, neonatal, and follow-up data on all survivors of 
VPT birth  to describe the type and incidence of disabilities at any particular 
age and to relate these to the aspects of care in the perinatal period (Lyon 2007). 
Additionally, Nuffield Council on Bioethics recommends that in a high-risk 
pregnancy, or when an unexpected EPT/VPT birth, parents receive up-to-date 
and consistent information that will inform their decision-making whether 
before birth, immediately after birth, or in the neonatal period. Information 
given should include the likelihood of their baby surviving based on the most 
up-to-date national and local survival rates, potential risks of disability, and the 
long-term consequences of the decisions made (Nuffield Council on Bioethics 
2006). 
It is essential that quality improvement be data driven. As a first step to 
quality improvement, data are used to determine one's baseline performance 
relative to a set of standards. As one begins to implement changes, data are used 
to track improvement. Linking aspects of perinatal care to longer-term outcome 
require the collection of relevant data during the neonatal period and at follow-
up. 
What is needed is a method of ongoing surveillance of outcome that (Lyon 
2007): 
 is easy to apply to all VPT infants; 
 is relatively cheap; 
 can link outcome to current perinatal care; 
 can report rapidly so that findings are relevant to current methods of care. 
 
Short-term outcome data 
There are two potential sources of short-term outcome data regarding VPT 
patients: primary and secondary databases. Primary databases  locally de-
signed neonatal databases and (inter)national neonatal networks  are speci-
fically created to address perinatal issues whereas secondary databases were 
originally designed for other purposes (Gould JB 2004). Examples of secondary 
datasets that have been used to evaluate quality of neonatal care are the hospital 
discharge database and the files that link birth certificates and death certificates. 
One of the required standards for hospitals involved in neonatal intensive 
care is that they collect data to measure their workloads and short-term out-
comes (British Association of Perinatal Medicine 2001). Pooling data would 
allow comparison of outcomes between similar units as well as give larger 
numbers for a meaningful analysis of the links between perinatal care and 
outcome. Nevertheless, comparison of data will only be meaningful if the same 
denominators and standardised definitions are used and the outcomes are 
adjusted for differences in case mix. Quality improvement activities for any 
given hospital are greatly facilitated by participating in a network. The networks 
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facilitate vital comparisons by standardising data definition and collection 
standards and their reports allow confidential risk-adjusted comparisons to peer-
institutions. Several NICU networks have been formed to evaluate the effective-
ness and efficiency of neonatal intensive care and facilitate the use of data for 
quality improvement. Examples include the Vermont Oxford Network, which 
was established in 1988 and now includes more than 950 hospitals around the 
world, the Australian and New Zealand Neonatal Network, EuroNeoNet, and 
many others (Horbar and Gould 2006). 
Nowadays, there is a general agreement for the need of mandatory national 
or regional perinatal-neonatal datasets for VPT babies. Pooled population data 
can be used for comparison of outcomes with other countries and health-care 
systems. National registers for VPT infants were established for example in 
1994 in Portugal (VLB Infants National Registry Group 2002) and in 2004 in 
Finland (Finnish Medical Birth Register). 
 
Long-term outcome data 
The optimum time to measure the health status of VPT children will depend on 
the reason for the assessment. It is generally agreed that 2 years, corrected for 
GA at birth, is the best time for initial follow-up data to be collected (Marlow 
2004, Lyon 2007), since at this age: 
 the findings are still likely to be relevant to current clinical practice; 
 the most serious neurological and sensory disability is likely to be identified, 
whereas at younger ages, it is believed that the diagnosis of disabling CP 
may not be accurate (Nelson and Ellenberg 1982) and the subject of transient 
neuroimpairment around 12 months of age has been well described (Brace-
well and Marlow 2002); 
 the effects of social and demographic factors will be minimised; and 
 it should still be relatively easy to achieve a good follow-up rate. 
Nowadays, there is a requirement that hospitals involved in neonatal intensive 
care develop and run a system for follow-up of all VPT babies who have been 
under their care (British Association of Perinatal Medicine 2001). 
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5. AIMS OF THE RESEARCH 
The general objective of this research was to describe the short-term and long-
term outcome for VLGA infants born in Estonia. 
The specific objectives were as follows: 
1. To identify the birth rate and short-term outcome (admittance to intensive 
care, mortality, neonatal morbidity, care, length of hospital stay, and centre 
differences) for VLGA infants born in Estonia in 2007–2008 (Study I) and to 
compare the data with that from VLGA infants born in 2002–2003 (Study 
II). 
2. To assess the outcome at 2 years of CA with respect to attained growth and 
both neurosensory and developmental impairment in a national cohort of 
VLGA infants born in 2007 and to compare the data with that from FT 
control infants (Study III). 
3. To establish the rate and characteristics of acute respiratory morbidity during 
the first two years of life in a national cohort of VLGA infants born in 2007 
and, again, to compare the data with that from FT control infants (Study IV). 
4. To analyse the risk factors associated with the adverse outcomes (death until 
hospital discharge and the presence of growth failure, CP, cognitive delay, 
language delay, and NDI at 2 years of CA) in VLGA infants (Study II, III). 
5. To analyse the risk factors associated with the adverse outcomes of RI 
(wheezing, recurrent wheezing (RW), hospitalisation, and antibiotic con-
sumption) during the first two years of life in VLGA and FT infants (Study 
IV). 
6. Altogether, to benchmark the quality of perinatal and neonatal services in 
Estonia and to identify key areas for ongoing national quality improvement 
initiatives.  
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6. PATIENTS AND METHODS 
6.1. Study design, study populations, and control cohorts 
This general population-based nationwide prospective cohort study of VLGA 
infants comprised all live-born infants in Estonia over a two-year study period 
2007–2008 (Study I). The cohort of 2007–2008 was compared with a historical 
cohort of 2002–2003 of live-born VLGA infants for the changes in care and 
short-term outcome after introduction of modern perinatal and neonatal care in 
Estonia (Study II). A sub-cohort of VLGA infants born in 2007 was selected for 
additional evaluation to study 2-year outcome in regard of attained growth, 
neurosensory and developmental impairment (Study III), and acute respiratory 
morbidity (Study IV). Studies III and IV  also compared the data from VLGA 
infants with that from individually matched FT control infants. Figure 5 outlines 
the study design, defines study populations, and describes registered outcome 
measures. 
All 360 live-born infants with a GA 22+0 to 31+6 GW born in Estonia from 
the 1st of January 2007 to the 31st of December 2008 or from the 1st of January 
2002 to the 31st of December 2003 were eligible for the short-term outcome 
studies (Studies I and II). Data were collected until death or discharge home,  
complete vascularisation of the  
Figure 6 outlines the flow chart of Studies III and IV. The national study 
cohort consisted of all 187 live-born infants with a GA 22+0 to 31+6 GW who 
were born in Estonia from the 1st of January 2007 to the 31st of December 2007. 
Of that group, 158 (84.5%) infants survived until discharge from hospital. In 
addition, two children died before the follow-up examination (one as a con-
sequence of severe chronic lung disease and the other as a consequence of long-
chain 3-hydroxyacyl-CoA dehydrogenase deficiency). One infant (reported to 
be healthy at the standard time of the follow-up examination by a phone 
interview) had moved abroad. VLGA infants with congenital anomalies were 
included in the analyses of the studies. In total, 155 infants, 99% of those alive 
at the CA of 2 years, underwent an assessment at that age. 
For each surviving VLGA infant, two matched FT (born at ≥37 GW) infants 
were identified from maternity ward databases using the following inclusion 
criteria: 1) no requirement for medical interference during the first week of life; 
2) born in the same geographical area; 3) having the same gender and natio-
nality; and 4) born as the first or the second infant after the expected date of 
birth of the VLGA infant. As a rule, for each VLGA infant the first FT control 
infant was selected. However, if the parents of the first FT control infant were 
not accessible or refused to participate, the second control was approached. In 
two cases, both families of identified FT control infants refused to participate in 
the follow-up. FT infants with a congenital disease diagnosed after the first 
week of life were included in the analyses of the studies. A total of 153 FT 
infants were enrolled in the study.  
retina had occurred. 
except for ROP, which was monitored until the 
Figure 5. 
 
Study design 
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EXPOSURE = VLGA; Exposed =      Unexposed =  
 
 
All VLGA infants born alive 
in Estonia in 2007–2008; 
followed until death  
or hospital discharge 
n = 360 
 
All VLGA infants born alive 
in Estonia in 20022003; 
followed until death  
or hospital discharge 
n = 264 
 
Surviving VLGA infants  
born in Estonia in 2007; 
follow-up assessment 
at 2 years of CA 
n = 155 
 
Individually matched controls 
born FT in Estonia in 2007; 
follow-up assessment 
at 2 years of age 
n = 153 
Study 
I, II 
Study 
III 
Study 
IV 
Main outcome variables registered: 
Study I, II 
Admittance to care 
Mortality 
Neonatal morbidity 
Interventions 
Length of hospital stay 
Centre differences 
Study III 
Mortality 
Growth 
Neurological assessment 
(PSOM, GFMCS) 
Ophthalmological assessment 
Hearing assessment 
BSID-III 
(composite scores for 
cognitive, language, and motor 
skills)
Study IV 
RI 
Wheezing 
RW 
Hospitalisations 
Antibiotic consumption 
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Figure 6. Flow chart of Studies III and IV 
 
 
6.2. Monitoring of patients and data collection  
Collection of perinatal data 
In 20072008, all live births at <32 GW in Estonia were recorded prospectively 
in a national neonatal research register. The register included 68 variables that 
were related to pregnancy risk factors, delivery, infant condition at birth, 
mortality, short-term morbidity, selected neonatal procedures, and length of 
hospital stay. For this study, discrepancies in the data were rechecked and 
missing data were added from the patient records of each hospital. For the 
VLGA births in 2002–2003, the same 68 variables were collected retro-
spectively from hospital records. The Estonian Medical Birth Registry was used 
to obtain the number of births and the number of VPT stillbirths, and to verify 
that all live-born VLGA infants were accounted for. 
 
Two-year follow-up assessment and parental interviews 
When the infants reached the CA of 24 (±1) months, the families were invited 
to one of two centres (Tallinn Children's Hospital and Children's Clinic of Tartu 
University Hospital) for a physical assessment by a paediatrician, a neurological 
examination by a child neurologist, and an assessment of development by a 
clinical child psychologist, using the BSID-III (Bayley 2006). The BSID-III 
provides age-standardised composite scores for cognitive, language, and motor 
skills with a mean score of 100 (standard deviation, SD, ±15) and subtest scores 
All VLGA infants born alive 
in Estonia in 2007 
 n = 187 
Infants surviving at discharge 
n = 158 
(84.5%) 
Individually matched FT infants 
n = 155 
Inclusion in follow-up 
n = 156 
 
Evaluated at 2 years of CA 
n = 155 
(99%) 
Deaths in NICU 
n = 29 
Deaths during the first two years of life 
n = 2 
Lost to follow-up 
n = 1 
Parents’ refusal 
n = 2
Evaluated at 2 years of age 
n = 153 
(99%) 
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for receptive communication, expressive communication, and fine motor and 
gross motor skills with a mean (SD) score of 10 (±3). 
In the neurological and developmental examination the PSOM (Paediatric 
Stroke Outcome Measure) was used by a neurologist. The PSOM measures 
neurological deficit and function across 5 subscales: right sensorimotor, left 
sensorimotor, language production, language comprehension, and cognitive/ 
behaviour yielding a final 10-point deficit score (de Veber et al. 2000).  
In infants with CP, the GMFCS (Palisano et al. 1997) was used to quantify 
motor function as follows:  
1)  Level 1, infants move in and out of sitting and floor sitting with both hands 
free to manipulate objects; infants crawl on hands and knees, pull to a stand 
and take steps holding on to furniture; infants walk between 18 months and 2 
years of age without the need for any assistive mobility device; 
2)  Level 2, infants maintain floor sitting but may need to use their hands for 
support to maintain balance; infants creep on their stomach or crawl on 
hands and knees; infants may pull to a stand and take steps holding on to 
furniture; 
3)  Level 3, infants maintain floor sitting when the low back is supported; 
infants roll and creep forward on their stomachs;  
4)  Level 4, infants have head control but trunk support is required for floor 
sitting; infants can roll to supine and may roll to prone; and 
5)  Level 5, physical impairments limit voluntary control of movement; infants 
are unable to maintain antigravity head and trunk postures in prone and 
sitting; infants require adult assistance to roll. 
Bodyweight, length, and head circumference were measured using routine 
methods. The results were related to the Estonian age- and gender-specific 
growth standards for 0–2 years (Kirss and Õun 2000) at time point of 2 years 
and were transformed into z-scores standardised for gender and age. The FT 
control group was representative of the general Estonian population of 2-year-
old children. The data from ophthalmological and hearing assessments were 
derived from the national follow-up programme. Hearing was assessed by 
otoacoustic emission and/or brainstem auditory evoked potential measurement. 
In addition, structured parental interviews were performed and socio-
demographic and environmental exposures (parental age and education, family 
structure and income, number of siblings in the same household, duration of 
breastfeeding, infants age at day care attendance) as well as the presence of RI 
during the first two years of life were recorded. The parents or legal guardians 
were specifically asked about the infant’s overall morbidity, the presence of 
acute respiratory symptoms, wheezing during RI, overall hospitalisations and 
hospitalisations due to RI, and the number of antibiotic courses prescribed in 
total and for RI. All RI cases treated at home were identified only by parental 
report whereas parental reports of hospitalisations were checked against the 
hospital databases to capture all admissions and their reasons. 
The examiners were aware of the birth status of the infants (premature vs. 
FT). 
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Definitions for short-term outcome and the organisation of perinatal care 
in Estonia 
Since the re-establishment of the Estonian Republic in 1991, Estonia has 
reformed its healthcare system successfully. Health insurance coverage has been 
extended to all children and pregnant women, which ensures equality of access 
to health services. 
Since 1992, all births in Estonia have been registered in the Estonian 
Medical Birth Registry without changes in the definitions or in the procedures 
of notification (National Institute for Health Development 2014). The definition 
of live birth of the World Health Organization is used (World Health 
Organization 1993). A newborn infant with a BW of at least 500 g carried to the 
22nd completed week of pregnancy, and with no characteristics of life is con-
sidered to be stillborn. GA is based on the best obstetrical assessment, using 
information from ultrasound measurements and the date of the last menstrual 
period. In Estonia, early ultrasound examination is done to confirm pregnancy 
and determine GA at 8 to 12 GW. At 19 to 21 GW a second ultrasound 
examination is performed to screen for congenital anomalies and developmental 
problems. The policy is not to terminate pregnancies with antenatally recog-
nised major congenital anomalies beyond 22 GW. 
Since the 1990s, Estonia has had a regionalised system of perinatal care: 
three tertiary level maternity hospitals that are located in the two major cities 
coordinate the care of high-risk pregnancies, including preterm births at  
<34 GW. These maternity hospitals provide nasal CPAP but no endotracheal 
ventilation. All newborns requiring the highest level intensive care are 
transported by a specialised paediatric intensive care team to one of the paediat-
ric intensive care units of the two regional children’s hospitals, which are 
located at a distance of up to 6 km from the tertiary level maternity hospitals 
and provide full intensive care, including long-term MV and neonatal surgery. 
Thus, all VLGA infants in our study who required intensive care with MV must 
be classified as outborn. VLGA infants not requiring MV are transported to one 
of the neonatal intermediate care units of the regional children’s hospitals. 
As a rule, during the study periods, all newborn infants who were born from 
22 GW onwards were resuscitated actively at birth by the attendant paediat-
ricians or by the specialised paediatric intensive care team. Until 2014, there is 
no national consensus on the management of ELGA infants born at the limit of 
viability. However, in cases of medical futility of treatment, care is generally 
withdrawn. 
In the present studies, the rate of regionalisation was defined as the pro-
portion of the VLGA infants born at the tertiary level maternity hospitals as 
well as the proportion of infants who were admitted to care and were cared for 
at these hospitals longer than 48 hours. Mothers were considered to have 
received antenatal corticosteroids if they received 1–2 doses of dexamethasone 
or betamethasone. Antenatal antibiotic treatment was defined as any antibiotic 
drug that was administered to the mother during delivery. Infants whose BW 
was below the 10th percentile for their GA, according to the Fenton Intrauterine 
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Growth Curves, were defined as small for GA (SGA) (Fenton 2003). BPD was 
diagnosed if there was oxygen dependency at 36 weeks’ PMA corresponding 
with moderate or severe BPD (Jobe and Bancalari 2001). NEC was divided into 
the stages defined by Bell et al. (Bell et al. 1978), PVL was defined in accor-
dance with data from de Vries et al. (de Vries et al. 1992), and PIVH was clas-
sified according to Papile et al. (Papile et al. 1978). Brain injury (PVL and/or 
PIVH) was reported if diagnosed at a post-mortem examination or by routine 
cranial ultrasound scanning, with the last scan performed before hospital 
discharge. “Severe cerebral lesion” was defined as PIVH grade 3–4 and/or PVL 
grade 2–4 upon neonatal cranial ultrasound scanning. Sepsis was defined as 
clinical signs of infection with a positive blood culture. The presence of ROP 
was reported using the International Classification for Retinopathy of Pre-
maturity (Committee for the Classification of Retinopathy of Prematurity 1984). 
Ophthalmological screening for ROP began during the fifth postnatal week and 
continued weekly or biweekly until the retina was completely vascularised or 
ROP had regressed. Survival without morbidity was defined by the absence of 
BPD, PIVH grade 3–4, PVL grade 2–4, ROP stage ≥3 with laser therapy, NEC 
stage ≥2, and⁄or blood culture-positive sepsis. 
 
Definitions for long-term outcome at 2 years of corrected age 
Infants, whose weight was below the 10th percentile according to the Estonian 
0–2 year age- and gender-specific growth curves, were defined as infants with 
growth failure at the CA of 2 years. CP was defined and classified in 
accordance with the guidelines of the Surveillance of Cerebral Palsy in Europe 
collaborative group (Surveillance of cerebral palsy in Europe 2000). Cognitive 
and language delay were categorised as severe, moderate, and mild using 
conventional SD-banded classification of standardised scores according to the 
BSID-III (Bayley 2006): severe <3 SD, moderate <2 SD to 3 SD, and mild 
<1 SD to 2 SD, respectively. Infants who functioned below the lower limit of 
the test were included with a score of –4 SD. Although the BSID-III has not 
been validated in Estonia, the original norms of the BSID-III were used and the 
scores for VLGA and FT control infants were compared. Developmental delay 
among VLGA infants was calculated according to the BSID-III original norms 
as well as to the FT control infants’ distribution. 
According to the PSOM (de Veber et al. 2000), each domain subscale 
(Sensorimotor Deficit, Language Deficit – Production, Language Deficit – 
Comprehensive, and Cognitive Deficit) was scored as 0 = no deficit, 0.5 = mild 
deficit, normal function, 1 = moderate deficit, slow function, or 2 =  severe 
deficit, missing function. 
The severity of neurodevelopmental impairment was defined as follows 
(British Association of Perinatal Medicine 2008): 
1)  normal development (no impairment detected in motor, cognitive, speech, 
hearing, and ophthalmological assessments); 
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2)  mild neurodevelopmental disability (CP with GMFCS level 1; Cognitive 
and/or Language Composite Scores 1 SD to 2 SD below norm; near normal 
vision and hearing); 
3)  moderate neurodevelopmental disability (CP with GMFCS level 2; Cogni-
tive and/or Language Composite Scores 2 SD to 3 SD below norm; hearing 
loss corrected with hearing aids; vision moderately reduced but better than 
severe visual impairment, or blind in one eye with good vision in the 
contralateral eye); and 
4)  severe neurodevelopmental disability (CP with GMFCS level 3, 4 or 5; 
Cognitive and/or Language Composite Score <3 SD below norm; no useful 
hearing even with hearing aids; blind or can only perceive light or light-
reflecting objects). 
Moderate and severe neurodevelopmental disabilities were taken together to 
represent NDI. 
Weight <10th percentile, CP, Cognitive Composite Score <70, Language 
Composite Score <70, and NDI were defined as adverse outcomes at a CA of 2 
years. 
All RI cases were identified by parental reports using the following criteria: 
1) episodes of illness characterised by the following symptoms (nasal conges-
tion, rhinorrhea, cough, sore throat, fever, and/or wheeze); or 2) physician-
diagnosed upper or lower (bronchitis, bronchiolitis, pneumonia) respiratory 
tract infections or acute otitis media. RI with gastrointestinal symptoms were 
included whereas gastroenteritis (e.g. rotavirus, norovirus) not accompanying 
RI were excluded. Recurrent RI was defined as the presence of a higher number 
of RI episodes than the population’s mean value. Wheezing was defined as an 
episodic wheeze due to RI whereas RW was defined as three or more episodes 
of wheezing due to RI during the study period. Wheezing, RW, and hospita-
lisation due to RI were considered to be adverse outcomes of RI. 
Socioeconomic status of the parents included: 1) educational level, cate-
gorised as low (no formal education or primary education), middle (secondary 
education), or high (higher professional education or university degree); and 2) 
monthly income per family member, categorised as low (<2,000 Estonian 
crowns/<128 EUR), medium (2,000–10,000 Estonian crowns/128–641 EUR), 
or high (>10,000 Estonian crowns/>641 EUR). 
Age at day care attendance was defined as chronological age at the first entry 
into day care centre. Breastfeeding included both exclusive and/or partial 
breastfeeding regardless of the amount of breast milk received. 
 
 
6.3. Statistical analysis and ethics 
Statistical analysis was performed using the statistical package Stata 12 
(StataCorp. 2011. Stata Statistical Software: Release 12. College Station, TX: 
StataCorp LP).  
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Descriptive statistics for categorical variables are presented as numbers and 
percentages and for continuous variables as means with the SD or medians with 
the interquartile range (IQR). Statistical comparisons between categorical 
variables were performed using chi-squared or Fisher’s exact test. Continuous 
variables were compared by Student’s t-test or Mann-Whitney U-test based on 
the distribution of variables. Significance level of 0.05 was used. Also, OR with 
95% CI were presented to describe difference in background characteristics 
between VLGA and FT infants. 
Differences in short-term outcomes until hospital discharge between the two 
cohorts of VLGA infants were presented as adjusted OR with 95% CI and 
calculated using multiple logistic regression models. The means of the com-
posite scores from the BSID-III were compared between different groups of 
infants using the mean difference and 95% CI. Multiple linear regression 
analysis was used to adjust the differences for the confounding variables. As-
sociations between the characteristics of RI and maturity at birth were assessed 
by Poisson regression and presented as incidence rate ratios (IRR) with 95% CI 
or by logistic regression and presented as OR with 95% CI depending on the 
type of variables (count or binary variables respectively). 
Simple and multiple logistic regression analyses were used to assess risk 
factors for the adverse outcome variables. Selected risk factors were first added 
in the simple model and only statistically significant risk factors (p 0.05) were 
then included in the multiple model. The results of the multiple logistic 
regression analyses are presented as adjusted OR with 95% CI. 
In a multiple logistic regression analysis to assess risk factors for death until 
discharge in Study II, both cohorts born in 20022003 and 20072008 were 
combined and following risk factors were tested: maternal age, complications of 
pregnancy (placental abruption, preeclamptic toxaemia, PPROM, chorioamnio-
nitis), birth at a tertiary level hospital, mode of delivery, antenatal steroid and 
antibiotics use, infant gender, GA, BW <10th percentile, multiple birth, 1-min 
Apgar score <5, and major neonatal morbidities (RDS, PIVH grade 34, NEC, 
and blood culture positive sepsis). 
In Study III, the following predictor variables were selected and studied in 
relation to the adverse outcomes (weight <10th percentile, presence of CP, 
Cognitive Composite Score <70, Language Composite Score <70, and NDI) at 
the infants' CA of 2 years: parents’ education and nationality, family income 
and structure, complications of pregnancy (placental abruption, preeclamptic 
toxaemia, PPROM, chorioamnionitis), birth at a tertiary level hospital, mode of 
delivery, antenatal steroid use, infant gender, GA, BW <10th percentile, multiple 
birth, 1-min Apgar score <5, major neonatal morbidities (BPD, PIVH grade 3–
4, PVL grade 2–4, NEC stage 2–3, ROP stage ≥3 with laser therapy, and 
positive blood culture sepsis), surfactant and postnatal steroid use, duration of 
MV, as well as weight <10th percentile and being fed only breast milk at 
hospital discharge. 
In Study IV, the following risk factors for the occurrence of recurrent RI and 
adverse outcomes of RI (wheezing, RW, and hospitalisation) were tested: 
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parents’ education and nationality, family income and structure, infant gender, 
GA, BW <10th percentile, multiple birth, BPD, duration of breastfeeding, age at 
day care attendance, as well as weight <10th percentile and NDI at the infants' 
CA of 2 years. The analysis described above in Study IV was carried out in 
VLGA and FT study cohorts as a whole as well as only for VLGA infants 
whereas the same selected risk factors were used. 
The Estonian Data Inspectorate gave permission to create the national neo-
natal research register. The studies were approved by the Ethics Review Com-
mittee on Human Research of the University of Tartu and written informed 
consent for follow-up studies was obtained from all the parent(s) or legal 
guardian(s).  
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7. RESULTS AND DISCUSSION 
7.1. Changes in care and short-term outcome for  
very low gestational age infants in Estonia 
In Estonia, 360 VLGA infants were born alive in 2007–2008 and 264 in 2002–
2003, with a rate of 11.3 and 10.2 per 1,000 live births, respectively (p = 0.184). 
The rate of VPT live births in Estonia showed no significant change between 
the two periods and was in the range of European countries involved in the 
EURO-PERISTAT Project (EURO-PERISTAT Project 2010). The number of 
live-born VLGA infants increased because of the growing number of births in 
Estonia.  
7.1.1. Perinatal characteristics 
The perinatal characteristics of the two cohorts of VLGA infants are sum-
marised in Table 3. There were no significant differences between the two 
cohorts in terms of mean GA, BW, or the proportions of infants who were of 
male gender or born SGA. A significant increase in infants from multiple births 
was found on comparison of the two periods; in addition, the average maternal 
age had increased. 
Regionalisation of perinatal care remained high: 87% of VLGA infants in 
2002–2003 and 90% in 2007–2008 were born at tertiary level maternity hos-
pitals. However, 45% of infants in 20022003 and 43% of infants in 20072008 
were transferred postnatally to the regional children's hospitals during the first 
hour of life. When regionalisation was defined as the proportion of VLGA 
infants who were born at tertiary level hospitals and were cared for at these 
hospitals longer than 48 hours, the rate of regionalisation decreased to 23% in 
20022003 and 27% in 20072008 (p = 0.243). The median age at the postnatal 
transfer for all VLGA infants was 1.2 hours in 20022003 and 1.4 hours in 
Positive trends in perinatal management were especially noticeable in more 
mature VLGA infants, born at 26–31 GW. This improvement was shown by a 
higher frequency of treatment with antenatal corticosteroids and maternal anti-
biotics, more births by caesarean section, and a lower proportion of babies with a 
1-min Apgar score <5 in 2007–2008 than in 2002–2003. Similarly, rates of 
antenatal steroid use increased from 2000 to 2009 up to 77% in the management 
of infants with 5001500 g BW in a study with prospectively collected register 
data from the Vermont Oxford Network (Soll et al. 2013). However, antenatal 
corticosteroid use in Europe (R egger et al. 2012), Canada (Shah et al. 2012), and 
Australia (Evans et al. 2007) still exceed rates reported by the Vermont Oxford 
centres in 2009 and by the present study in 20072008 in Estonia. Although the 
optimal mode of birth for VLGA infants is controversial, we found an increasing 
rate of caesarean delivery in the present study (42% in 20022003 vs. 54% in 
20072008). Higher rates, up to 72% of caesarean section for 5001500 g BW 
infants, have been reported from the United States (Soll et al. 2013). 
ü
2007–2008. 
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7.1.2. Admittance for care and survival 
Tables 4 and 5 summarise the principal data of the results. A significantly 
higher proportion of infants born at 22–25 GW were admitted for care in 2007–
2008 than in 2002–2003. The survival rate until discharge increased signifi-
cantly from 78% in 2002–2003 to 85% in 2007–2008 (p = 0.041) if live-born 
VLGA infants were included in the denominator. The lower limit of viability, 
defined as the lowest GA with a survival rate of over 50%, was 25 GW in both 
cohorts, although it should be noted, that 48% of infants born at 24 GW 
survived until discharge in 20072008 (Table 5). 
The median age at death for live-born VLGA infants was 1.7 (IQR 0.1–9.5) 
days in 2002–2003 and 3.6 (IQR 0.6–9.3) days in 2007–2008 (p = 0.183). There 
were no significant differences detected in the proportions of infants who died 
in the early neonatal (16% in 2002–2003 vs. 11% in 2007–2008; p = 0.065), late 
neonatal (4 vs. 3%, respectively; p = 0.457) or post-neonatal periods (2 vs. 1%, 
respectively; p = 0.586). Of infants who were admitted for intensive care and 
died, a decision had been made to withdraw treatment in 14 and 31% of cases  
(p = 0.080), respectively. 
However, it is crucial to account as well as for stillbirths and late termina-
tions of pregnancy when comparing VPT births internationally (Evans and Le-
vene 2001). In Estonia, the policy is not to terminate pregnancies with ante-
natally recognised, major congenital anomalies beyond 22 GW. The survival 
rate until discharge increased from 69% in 2002–2003 to 75% in 2007–2008  
(p = 0.087) if stillborn and live-born VLGA infants were included in the deno-
minator. According to the Estonian Abortion Registry (National Institute for 
Health Development 2014), only three pregnancies were ended at 22– 
23 GW during this period. The MOSAIC study from 10 European regions 
reported higher rates (0.9–21.5%) for the termination of pregnancies among the 
cohort of pregnancies that ended at 22–31 GW, for which only 48–74% of 
births were discharged from hospital alive (Draper et al. 2009). 
Survival rates of VLGA infants achieved in the later cohort in Estonia are 
good when compared to similar population-based and multicentre studies shown 
in Tables 6 and 7. 
In the multiple analysis to determine the risk factors for death, death was 
affected by GA (OR 0.66; 95% CI 0.57–0.75), 1-min Apgar score <5 (2.67; 
1.49–4.79), and PIVH grade 3–4 (8.79; 4.71–16.42). 
 
 
7.1.3. Neonatal morbidity 
The incidence of major neonatal morbidities was not significantly different 
between the two studied cohorts, except for a decrease in PIVH grade 3–4 in the 
cohort born in 2007–2008 (Table 8). Reported morbidity rates for VPT infants 
between different countries, presented in Table 6 for VLGA/VLBW infants and 
in Table 7 for ELGA/ELBW infants, vary considerably because of differences 
in criteria for selection, which makes direct comparison difficult. Nevertheless,  
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60 
it can be concluded cautiously that, in the present study in Estonia, the inci-
dence of major neonatal morbidities, especially the rate of severe PIVH, ROP, 
and NEC, was higher than in other reports (Darlow et al. 2003, Vanhaesebrouck 
et al. 2004, Markestad et al. 2005, Tommiska et al. 2007, Fischer et al. 2009, 
EXPRESS 2010, Murphy et al. 2010, Zeitlin et al. 2010a). 
Morbidity-free survival did not increase significantly over time. Overall, 
44% of VLGA infants who were born in 2007–2008 survived until discharge 
without major, early morbidities, whereas only two infants born at 22–25 GWs 
were free of them. It was 29 completed GW as milestone for survival over 50% 
without any major morbidities at discharge (Table 5). Differences in morbidity-
free survival for VLGA infants born in 2002–2003 and 2007–2008 by GA are 
shown in Figure 7. While survival increased between the two studied periods, 
morbidity-free survival remained unchanged. 
 
7.1.4. Neonatal interventions and length of hospital stay 
In 2007–2008, the care strategies adopted were significantly less invasive 
(Table 9). The changes included decrease in intubation after birth, MV, ino-
tropic therapy, and the administration of antibiotics, with the use of vancomycin 
almost halved. In addition, the median duration of MV and antibiotic treatment 
was shortened, whereas in contrast, surgical closure of PDA was used more 
often in 2007–2008 than in 2002–2003. 
 Changes in the use of both invasive and non-invasive respiratory support 
have been reported also in other neonatal networks. A study from the Vermont 
Oxford Network with prospectively collected register data for 355,806 infants 
born from 2000 to 2009, reported a significant increase of less-invasive 
methods of respiratory support, such as nasal CPAP, use of nasal ventilation, 
and high-flow nasal cannula (Soll et al. 2013), whereas most of the changes 
were observed within each of four BW strata (501750 g, 7511000 g, 
10011250 g, 12511500 g). In southern Sweden between 1995 and 2004, 
Lundqvist et al. (Lundqvist et al. 2009) reported an increased use of assisted 
ventilation of infants <25 GW, but greater use of CPAP in infants 25 to 28 GW. 
In Switzerland, Rüegger et al. (Rüegger et al. 2012) reported that the use of 
CPAP increased from 43% in 1996 to 73% in 2008 in VPT infants. 
 Whereas the use of postnatal steroids reached the zenith in the late 1990s 
with 24% of all VLBW infants exposed in 2000 and decreased to 8% in 2009 in 
the United States (Soll et al. 2013), the use of postnatal steroids remained low 
during the both studied periods in Estonia, 4% in 20022003 and 5% in 
20072008. 
Improved survival rates in the later period were not associated with a longer 
hospital stay. The median length of hospital stay for infants who were admitted 
for care but died was 5 days in both cohorts (p = 0.968). For survivors, the 
median length of stay was 55 (IQR 41–77) days in 2002–2003 and 52 (IQR 37–
79) days in 2007–2008 (p = 0.379). 
  
61
 
 
 
D
ef
in
iti
on
s:
 n
eo
na
ta
l m
or
bi
di
tie
s 
de
fin
ed
 a
s 
su
pp
le
m
en
ta
l o
xy
ge
n 
re
qu
ire
d 
at
 ≥3
6 
w
ee
ks
’ P
M
A
, p
re
se
nc
e 
of
 P
IV
H
 g
ra
de
 3
–4
, P
V
L 
gr
ad
e 
2–
4,
 
R
O
P 
st
ag
e 
≥3
 w
ith
 la
se
r t
he
ra
py
, N
EC
 st
ag
e 
≥2
, a
nd
⁄o
r b
lo
od
 c
ul
tu
re
-p
os
iti
ve
 se
ps
is
. 
 Fi
gu
re
 7
. D
iff
er
en
ce
s i
n 
sh
or
t-t
er
m
 o
ut
co
m
e 
at
 h
os
pi
ta
l d
is
ch
ar
ge
 fo
r V
LG
A
 in
fa
nt
s b
y 
G
A
 b
or
n 
in
 E
st
on
ia
 in
 2
00
2
20
03
 a
nd
 2
00
7
20
08
 
  
 
010203040506070809010
0
22
-2
3
G
W
n 
= 
13
20
02
/3
22
-2
3
G
W
n 
= 
17
20
07
/8
24
-2
5
G
W
n 
= 
32
20
02
/3
24
-2
5
G
W
n 
= 
55
20
07
/8
26
-2
7
G
W
n 
= 
50
20
02
/3
26
-2
7
G
W
n 
= 
68
20
07
/8
28
-2
9
G
W
n 
= 
67
20
02
/3
28
-2
9
G
W
n 
= 
79
20
07
/8
30
-3
1
G
W
n 
= 
10
2
20
02
/3
30
-3
1
G
W
n 
= 
14
1
20
07
/8
D
ea
d
A
liv
e 
w
ith
 n
eo
na
ta
l m
or
bi
di
tie
s
A
liv
e 
w
ith
ou
t n
eo
na
ta
l m
or
bi
di
tie
s
%
62
 
Ta
bl
e 
9.
 In
te
ns
iv
e 
ca
re
 in
te
rv
en
tio
ns
 fo
r V
LG
A
 in
fa
nt
s b
or
n 
in
 E
st
on
ia
 in
 2
00
2–
20
03
 a
nd
 2
00
7–
20
08
  
  
22
–2
5 
G
W
 
 
26
–3
1 
G
W
 
 
22
–3
1 
G
W
 
 
20
02
–2
00
3 
(n
 =
 3
4)
 
20
07
–2
00
8 
(n
 =
 6
9)
 
p 
va
lu
e 
20
02
–2
00
3 
(n
 =
 2
14
) 
20
07
–2
00
8 
(n
 =
 2
84
) 
p 
 
va
lu
e 
20
02
–2
00
3 
(n
 =
 2
48
) 
20
07
–2
00
8 
(n
 =
 3
53
) 
p 
va
lu
e 
En
do
tra
ch
ea
l i
nt
ub
at
io
n 
du
rin
g 
th
e 
1s
t  h
ou
r o
f l
ife
 
  3
4 
(1
00
) 
  6
2 
(9
0)
 
0.
09
2 
10
1 
(4
7)
 
  8
6 
(3
0)
 
<0
.0
01
 
13
5 
(5
4)
 
14
8 
(4
2)
 
  0
.0
02
 
Su
rf
ac
ta
nt
 th
er
ap
y 
  2
8 
(8
2)
 
  6
8 
(9
9)
 
0.
00
5 
  9
5 
(4
4)
 
13
6 
(4
8)
 
  0
.4
39
 
12
3 
(5
0)
 
20
4 
(5
8)
 
  0
.0
47
 
M
V
 
  3
4 
(1
00
) 
  6
9 
(1
00
) 
 
14
3 
(6
7)
 
15
4 
(5
4)
 
  0
.0
05
 
17
7 
(7
1)
 
22
3 
(6
3)
 
  0
.0
36
  
D
ur
at
io
n 
of
 M
V
, h
, m
ed
ia
n 
(I
Q
R
) 
30
0 
(4
8–
67
2)
 
21
6 
(7
2–
76
8)
 
0.
57
4 
16
8 
(7
2–
43
2)
 
  7
2 
(2
4–
16
8)
 
<0
.0
01
 
16
8 
(7
2–
48
8)
 
  9
6 
(4
8–
21
6)
 
<0
.0
01
 
In
do
m
et
ha
ci
n 
or
 ib
up
ro
fe
n 
fo
r P
D
A
  
  1
9 
(5
6)
 
  3
3 
(4
8)
 
0.
44
2 
  4
6 
(2
1)
 
  6
4 
(2
3)
 
  0
.7
82
 
  6
5 
(2
6)
 
  9
7 
(2
7)
 
  0
.7
30
 
Su
rg
ic
al
 li
ga
tio
n 
fo
r P
D
A
  
   
 4
 (1
2)
 
  2
4 
(3
5)
 
0.
01
8 
   
 4
 (2
) 
  3
0 
(1
1)
 
<0
.0
01
 
   
 8
 (3
) 
  5
4 
(1
5)
 
<0
.0
01
 
In
fa
nt
s t
re
at
ed
 a
t l
ea
st
 o
nc
e 
w
ith
 a
nt
ib
io
tic
s  
  3
3 
(9
7)
 
  6
9 
(1
00
) 
0.
33
0 
20
9 
(9
8)
 
26
2 
(9
2)
 
  0
.0
09
 
24
2 
(9
8)
 
33
1 
(9
4)
 
  0
.0
31
 
D
ur
at
io
n 
of
 a
nt
ib
io
tic
 
tre
at
m
en
t, 
da
ys
, m
ed
ia
n 
(I
Q
R
) 
  2
1 
(3
–4
1)
 
  1
2 
(4
–3
1)
 
0.
88
6 
  1
9 
(1
1–
31
) 
   
 8
 
(5
–1
4)
 
<0
.0
01
 
  1
9 
(1
0–
33
) 
   
 8
 
(5
–1
6)
 
<0
.0
01
 
In
fa
nt
s t
re
at
ed
 w
ith
 
va
nc
om
yc
in
 
  1
6 
(4
7)
 
  3
1 
(4
5)
 
0.
83
8 
  7
8 
(3
6)
 
  4
1 
(1
4)
 
<0
.0
01
 
  9
4 
(3
8)
 
  7
2 
(2
0)
 
<0
.0
01
 
In
fa
nt
s t
re
at
ed
 w
ith
 
de
xa
m
et
ha
so
ne
* 
   
 3
 (2
1)
 
   
 9
 (2
4)
 
0.
99
9 
   
 5
 (3
) 
   
 7
 (3
) 
  0
.9
99
 
   
 8
 (4
) 
  1
6 
(5
) 
  0
.5
29
 
In
fa
nt
s t
re
at
ed
 w
ith
 
in
ot
ro
pe
s 
  2
6 
(7
6)
 
  5
5 
(8
0)
 
0.
70
6 
  9
7 
(4
5)
 
  7
5 
(2
6)
 
<0
.0
01
 
12
3 
(5
0)
 
13
0 
(3
7)
 
  0
.0
02
 
D
at
a 
ar
e 
sh
ow
n 
in
 n
um
be
rs
 (p
er
ce
nt
ag
es
) o
f i
nf
an
ts
 a
dm
itt
ed
 fo
r c
ar
e 
un
le
ss
 o
th
er
w
is
e 
in
di
ca
te
d.
 
*D
at
a 
ar
e 
sh
ow
n 
in
 n
um
be
rs
 (p
er
ce
nt
ag
es
) o
f s
ur
vi
vo
rs
. 
  
 
63 
7.1.5. Centre differences  
When the neonatal intensive care strategies and the mortality and morbidity 
rates between the groups of VLGA infants born in the three tertiary level mater-
nity hospitals were compared, some differences were found in the neonatal 
management during the later study period 2007–2008. The mean GA and BW 
as well as the proportion of infants born at <26 GW did not differ between the 
groups. However, the early interventions were less invasive in hospital A (Table 
10). Namely, significantly higher proportion of infants born in this hospital 
were treated with early CPAP and a lower proportion of infants needed endo-
tracheal intubation during the first hour of life and/or MV during the entire 
hospital stay. Less invasive care strategies were introduced in hospital A during 
the later study period 2007–2008. Among VLGA infants born in hospital A in 
2007 compared with the infants born in 2008, the rate of early CPAP was 51 vs. 
73% whereas the rate of intubation during the first hour of life was 41 vs. 20% 
and of MV until discharge 51 vs. 43%. Recently higher rates of early CPAP and 
lower rates of MV have been reported among ELGA infants compared with the 
whole Estonian study cohort (Table 9). For example, a single-centre outcome 
data of infants born at 23–27 GW who have been managed by a new mode of 
surfactant administration without intubation showed that 68% of infants stayed 
on CPAP on day 3 and the rate of MV was 59% during the entire hospital stay 
(Klebermass-Schrehof et al. 2013). From hospital A, 41% of VLGA infants 
were transported to the paediatric intensive care unit and 59% to the neonatal 
intermediate care unit whereas from hospital B and C, 95 and 87% of infants, 
respectively, were transported to the paediatric intensive care units. The mean 
age of infants at the transport was 115 hours for infants born in hospital A and 
four hours for infants born in hospital B and C. 
Any significant differences were found in the rates of mortality and major 
neonatal morbidities (BPD, PIVH grade 3–4, PVL grade 2–4, NEC stage 2–3, 
positive blood culture sepsis >72 hours, and ROP stage ≥3 with laser therapy) 
between the groups of VLGA infants born in hospital A, B, or C. However, the 
rate of pneumothorax was the highest among infants born in Hospital A and the 
rate of morbidity-free survival was significantly higher among infants born in 
hospital A than in hospital B (Table 10). The difference in morbidity-free survi-
val between hospital A and B remained statistically significant after adjustment 
for gender, BW, GA, BW 10th percentile, multiple birth, antenatal cortico-
steroid treatment, and Apgar score at birth.  
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7.2. Long-term outcome for very low gestational  
age infants at 2 years of corrected age in Estonia 
The follow-up studies regarding growth, neurosensory and developmental im-
pairment (Study III), and respiratory morbidity (Study IV) at 2 years of CA, 
were carried out in survived VLGA infants and their FT controls born in 2007. 
The mean age at assessment for the VLGA group was 24.2 (SD 1.1) corrected 
months and for the FT control group it was 24.4 (SD 0.8) months, with a mean 
difference of 0.15 months (95% CI: –0.06–0.36). 
The background characteristics of the final study population (155 VLGA and 
153 FT infants in the control group) are summarised in Tables 11 and 12. Three 
VLGA infants had a congenital anomaly or a syndrome of clinical significance  
 
Table 10. Centre differences in neonatal management and morbidity for VLGA infants 
born in Estonia in 2007–2008 and admitted for care 
 
 Tertiary level maternity 
hospitals 
 
 
p  
value 
 
 
OR (95% CI) A 
(n = 140) 
B 
(n = 76) 
C 
(n = 103) 
Early CPAP 85 (61)   3 (4)   6 (6) <0.001* 
<0.001** 
  0.735*** 
37.6 (11–125) 
25.0 (10–61) 
  1.5 (0.4–6.2) 
Endotracheal 
intubation during 
the 1st hour of life 
45 (32) 52 (68) 42 (41) <0.001* 
  0.165** 
<0.001*** 
  4.6 (2.5–8.3) 
  1.5 (0.9–2.5) 
 3.2 (1.7–5.9) 
Surfactant 
therapy 
57 (41) 60 (79) 69 (67) <0.001* 
<0.001** 
  0.023*** 
  5.3 (2.8–10.1) 
  2.4 (1.4–4.1) 
  2.2 (1.4–4.3) 
MV 67 (48)  60 (79) 69 (67) <0.001* 
  0.003** 
  0.078*** 
  4.1 (2.1–7.8) 
  2.2 (1.3–3.8) 
  1.9 (0.7–5.1) 
Pneumothorax 20 (14)   6 (8)   2 (2)   0.168* 
  0.003** 
  0.172*** 
  1.9 (0.7–5.1) 
  5.6 (1.6–19.2) 
  2.9 (0.7–11.8) 
Morbidity-free 
survival until 
discharge 
62 (44) 45 (59) 53 (51)   0.036* 
  0.269** 
  0.303*** 
  1.8 (1.0–3.2) 
  1.3 (0.8–2.2) 
  1.4 (0.8–2.5) 
Data are shown as numbers (percentages) of infants admitted for care. 
*Statistical difference between hospital A and B. 
** Statistical difference between hospital A and C. 
*** Statistical difference between hospital B and C. 
Definitions: morbidity-free survival defined as no supplemental oxygen required at  
≥36 weeks’ PMA, absence of PIVH 3–4, PVL grade 2–4, ROP stage ≥3 with laser 
therapy, NEC stage ≥2, and ⁄ or blood culture-positive sepsis. 
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7.2.1. Survival 
The overall two-year survival rate for the VLGA infants born alive in Estonia in 2007 
was 83%, whereas it was 47% for infants born at 22–25 weeks and 92% for infants born 
at 26–31 weeks. 
The survival of ELGA and VLGA infants in Estonia during the first two years of life 
was higher (Wood et al. 2000, Rattihalli et al. 2011) or comparable (Rijken et al. 2003, 
Vohr et al. 2005b, Fily et al. 2006, De Groote et al. 2007, Munck et al. 2010) to that 
reported in several other population-based or multicentre studies, although higher 
survival rates have also been reported (Bode et al. 2009, Doyle et al. 2011, Serenius et 
al. 2013) (Tables 13 and 14). 
 
 
7.2.2. Growth 
The VLGA infants had significantly lower bodyweight, length, and smaller head 
circumference when compared with infants from the FT control group (Table 15). The 
mean difference in weight was 973 g (0.66 z-scores; 1116 g (0.76 z-scores) for boys and 
787 g (0.51 z-scores) for girls). For body length, the mean difference was 1.3 cm (0.36 
z-scores; 1.5 cm (0.38 z-scores) for boys and 1.2 cm (0.32 z-scores) for girls), and for 
head circumference it was 0.5 cm (0.25 z-scores; 0.6 cm (0.29 z-scores) for boys and 
0.3 cm (0.19 z-scores) for girls). All of the z-scores were significantly different between 
study groups. Among all the VLGA infants, 31% were below the 10th percentile by 
bodyweight (38% of boys and 22% of girls) of Estonian 2-year child growth chart, 
while 65% of them were more mature infants born at 28 to 31 GW. The comparable 
numbers were 23% for length (23% of boys and 22% of girls) and 21% for head 
circumference (22% of boys and 19% of girls). 
The duration of breastfeeding was not associated with a weight of <10th percentile at 
the follow-up examination. 
(Tetralogy of Fallot, congenital laryngeal stenosis, and Hallermann-Streiff syndrome) 
and two FT infants had a congenital disease (toxoplasmosis and hypothyreosis) diag-
nosed after the first week of life. VLGA infants were more likely to be from low-in-
come families than FT infants and their parents were less likely to have higher edu-
cation. None of the VLGA infants required oxygen therapy at home. BPD was diag-
nosed in 29 (19%) of the VLGA infants; in 19 (49%) and 10 (9%) infants born at 22–27 
and 28–31 GW, respectively. During the first year of life, 12 (8%), and during the 
second year seven (5%) VLGA infants were given a monthly injection of respiratory 
syncytial virus monoclonal antibody during peak respiratory syncytial virus season. The 
mean duration of partial and/or exclusive breastfeeding in VLGA infants was signi-
ficantly shorter than in FT infants, 147 days (95% CI: 119175) for VLGA and 308 
days (95% CI: 273342) for infants in the FT control group. Most infants were cared for 
at home in both groups. Only one infant in each group went to day care before the age 
of 12 months. At the age of 18 months, 5% of VLGA and 14% of FT infants attended 
some form of organised day care. 
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7.2.3. Neurosensory outcomes 
In the present study, no impairment with respect to neurosensory and develop-
mental outcomes was found in 93 (60%) of VLGA infants. 
Throughout the world, the condition that is associated most commonly with 
a VPT birth is CP. The prevalence of CP in the present study was 90.9 per 1,000 
VLGA live births (17/187). For the group of survivors at the CA of 2 years, the 
prevalence of CP was 11% (18% for infants born at 22–25 GW and 10% for 
infants born at 26–31 GW). From VLGA infants with CP, 65% were born at 28 
to 31 GW. Of the 17 infants who had CP, 13 (8% of VLGA infants) had a 
GMFCS level of 2–5. The most common type of CP was spastic diplegia (seven 
cases). The second most common neurological problem was hydrocephalus, 
which was diagnosed in eight infants (5%), five of whom had CP. One child 
had epilepsy and needed antiepileptic therapy. 
The prevalence of CP from previously reported follow-up studies of ELGA/ 
ELBW and VLGA/VLBW infants is shown in Tables 13 and 14. 
The prevalence of severe impairments of hearing and vision among VLGA 
infants in the present study remained reassuringly low (Tables 13 and 14). 
Neonatal screening for both conditions is well established in Estonia, and laser 
coagulation provides good ocular results for the treatment of ROP. Although 13 
infants (8%) had received laser therapy for both eyes, only one child was blind 
in one eye at follow-up examination. Two (1%) infants suffered from hearing 
impairment that necessitated hearing rehabilitation. 
Of greatest concern was the finding that while 6% of VLGA infants were 
SGA at birth and 55% were <10th percentile of weight at discharge, at the CA 
age of 2 years, 31% of them (44% of infants born before 28 GW and 27% of 
those born at 28 to 31 GW) were still below the 10th percentile by bodyweight 
of Estonian 2-year child growth chart. However, previously the Neonatal 
Research Network of the National Institute of Child Health and Human 
Development had also reported that while 16% of ELBW infants were SGA at 
birth, by 36 weeks of PMA 89% had growth failure. Furthermore, by CA of 18 
to 22 months, 40% still were at less than the 10th percentile for weight, length, 
and head circumference (Dusick et al. 2003). 
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7.2.4. Developmental outcomes 
The descriptive statistics for the BSID-III composite and subtest scores for 
VLGA infants and FT controls are listed in Table 16. VLGA infants had signifi-
cantly lower mean Cognitive, Language, and Motor Composite Scores when 
compared with FT control group, with the magnitude of all differences between 
groups in excess of approximately 0.5 SD. The estimated difference between 
the study groups was 8.6 points (95% CI: 5.3–11.7) for the Cognitive, 7.1 (4.0–
10.2) for the Language, and 8.9 (5.3–12.5) for the Motor Composite Score. 
After adjustment for family income, family structure, and parents’ education, 
the mean differences did not change. If infants with CP, blindness, and deafness 
were excluded, the mean group differences decreased to 5.5 (95% CI: 2.7–8.3), 
4.8 (1.9–7.7), and 4.7 points (1.6–7.9), respectively. 
The means (SD) of the Cognitive and Motor Composite Scores by BSID-III 
were significantly higher for VLGA infants born at the tertiary level maternity 
hospitals when compared with those born at local hospitals (95.5 (15.4) vs. 85.4 
(13.4) (p = 0.026) and 95.5 (18.0) vs. 79.8 (17.0) (p = 0.002), respectively) 
whereas the mean Language Composite Scores were similar. P-values for the 
differences of the means of Cognitive and Motor Composite Scores from a 
multiple model adjusted for variables not under control of the clinician (GA, 
gender, BW 10th percentile, and multiple birth) remained statistically signi-
ficant (p = 0.046 and p = 0.010, respectively). After adjustment, the estimated 
difference between the study groups was 9.2 points (95% CI: 0.2–18.2) for the 
Cognitive, 5.2 (-3.6–13.9) for the Language, and 13.9 (3.3–24.4) for the Motor 
Composite Score. 
There were no significant differences in the mean composite scores between 
the subgroups born at 22–25 and 26–31 GW (Table 16). This may be explained 
by the small number of infants in the group of more immature infants, and by 
withdrawal of treatment in four cases during the neonatal period in the subgroup 
of 22–25 GW versus two cases in the subgroup of 26–31 GW.  
The proportion of VLGA infants with cognitive delay was 17% (12% mild, 
3% moderate, and 2% severe delay) and the proportion of VLGA infants with 
language delay was 33% (23% mild, 6% moderate, and 4% severe delay). 
Infants born at 28 to 31 GW comprised 60% of all VLGA infants with cognitive 
delay and 75% of all VLGA infants with language delay. Mild neurodevelop-
mental disability was found in 28% and NDI in 12% (5% moderate and 7% 
severe disability) of VLGA infants. 
Previously within-group analyses for VPT children have shown a linear 
correlation between IQ and GA (Bhutta et al. 2002, Serenius et al. 2013). Data 
from the present study on the BSID-III composite scores of VLGA infants by 
GW are presented in Table 17 and in Figure 8. Surprisingly no linear relation 
between mean/median composite scores and GA was found that could be 
caused by the small number of infants studied. 
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Consistent with previous studies (Anderson et al. 2010, Charkaluk et al. 2010), 
we found the Language Composite Scores to be the lowest in VLGA infants. 
Surprisingly, however, Language Composite Scores were also the lowest in the 
FT control group (Table 16). Expressive communication was delayed more than 
receptive communication in both groups. We speculate that the reasons for 
delayed development of language might include cultural differences between 
the populations of Estonia and the United States, given that the BSID-III was 
standardised in the United States and not in Estonia. 
 
 
7.2.5. Composite outcome 
Data on composite outcome of VLGA infants by GA are presented in Figure 9. 
 
Definitions: the severity of the impairments are defined as follows: 1) normal develop-
ment (no impairment detected in motor, cognitive, speech, hearing and ophthalmolo-
gical assessment); 2) mild neurodevelopmental disability (CP with GMFCS level 1, 
Cognitive and/or Language Composite Scores 1 to 2 SD below norm, near normal 
vision and hearing); 3) moderate neurodevelopmental disability (CP with GMFCS level 
2, Cognitive and/or Language Composite Scores 2 to 3 SD below norm, hearing loss 
corrected with aids, vision moderately reduced but better than severe visual impairment, 
or blind in one eye with good vision in the contralateral eye); and 4) severe neuro-
developmental disability (CP with GMFCS level 3, 4 or 5, Cognitive and/or Language 
Composite Score <3 SD below norm, no useful hearing even with aids, blind or can 
only perceive light or light-reflecting objects). 
 
Figure 9. Survival and neurodevelopmental outcome for VLGA infants by GA born in 
Estonia in 2007 at 2 years of CA 
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Composite outcome data for VLGA infants calculated according to the different 
outcome measures are shown in Table 18. The proportion of infants with 
moderate or severe cognitive and motor delay was similar despite the outcome 
measurement used. However, with the use of the PSOM, language delay could 
be overestimated as the PSOM measures Language Deficit Production and Lan-
guage Deficit Comprehensive scores separately. Additionally with the use of the 
PSOM, a larger proportion of infants were diagnosed with mild motor delay. 
Consequently, our results demonstrate that the PSOM as a stroke-specific out-
come measure should be used with caution for evaluation of VPT children in 
general. 
 
 
Table 18. Composite outcome for 155 VLGA infants born in Estonia in 2007 at 2 years 
of CA according to the BSID-III and the PSOM  
 
 BSID-III  
reference 
BSID-III 
control distribution 
PSOM 
Cognitive delay    
   Mild 19 (12) 45 (29) 13 (8) 
   Moderate   5 (3)   7 (5)   7 (5) 
   Severe   3 (2)   7 (5)   8 (5) 
Language delay    
   Mild 36 (23) 23 (15) 39 (25) 
   Moderate   9 (6)   9 (6) 31 (20) 
   Severe   6 (4)   6 (4) 21 (14) 
Motor delay    
   Mild 17 (11) 23 (15) 37 (24) 
   Moderate   4 (3)   6 (4)   8 (5) 
   Severe   9 (6) 11 (7) 11 (7) 
Data are shown in numbers (percentages) of examined infants. 
 
 
7.2.6. Risk factors for adverse long-term outcomes 
Factors that had a significant effect on the 2-year adverse outcomes (weight 
<10th percentile, CP, cognitive delay, language delay, and NDI) in the present 
study included antenatal steroid use, male gender, and neonatal complications 
such as poor neonatal growth, severely abnormal cerebral findings on neonatal 
ultrasound screening, BPD, and NEC (Table 19), all similar to the findings from 
previous studies (Ehrenkranz et al. 2006, Bode et al. 2009, Munck et al. 2010). 
In the present study, poor postnatal growth was associated with weight <10th 
percentile at 2 years of CA but not with a less favourable cognitive outcome, 
which is not consistent with the earlier literature (Ehrenkranz et al. 2006). The 
biggest concern is that, in spite of the withdrawal of treatment because of severe 
PIVH in five neonates (3% of the live-born infants), the existence of severe 
cerebral lesions was still the most significant risk factor for impairment among 
all the domains studied at follow-up. More advanced GA correlated with better 
composite neurodevelopment but not with each individual outcome studied. 
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Infants in the VLGA population were more likely to be from low-income 
families than infants in the FT population, and the parents of VLGA infants 
were less likely to have undertaken higher education than those of infants in the 
FT control group (Table 12). Although parental education level and social class 
have already been shown to be risk factors for poor cognitive development of 
premature children at the age of 2 years (Fily et al. 2006, Charkaluk et al. 2010), 
in our study population the demographic variables did not affect the results. On 
average, the children in the present study stayed at home with their mothers for 
an extended period of time after their birth (Table 12). Staying at home without 
exposure to a more diverse and stimulating environment should increase the 
effect of parental education level on a child’s development. Nonetheless, in the 
present study, the latter effect might have been diminished by the impact of 
perinatal risk factors or might become significant during later stages of develop-
ment. 
 
7.3. Acute respiratory morbidity during the first two years  
of life in very low gestational age infants in Estonia 
7.3.1. Frequency of respiratory infections 
The mean annual number of RI was 1.5 during the first and 1.9 during the 
second year of life in the VLGA as well as in the FT group. If, however, the 
VLGA group was divided into those born at 22–27 GW and those at 28– 
31 GW, significant differences during the first year of life were observed. 
Namely the mean number of RI episodes per child favoured babies with higher 
GA (Table 20). The frequency of annual RI divided into none, 1–3, and >3 
episodes was similar between the VLGA and the FT group during the first as 
well as the second year of life. The proportion of infants with RI during the first 
year of life was higher among those initially discharged between April and 
September as compared with those discharged from October to March (72 vs. 
59%; p = 0.008). 
In the present study, we describe lower mean annual number of RI for 
VLGA infants as well as for FT infants than in the United States (5.1 episodes 
per child-year during the first three years of life) and in Germany (1.5 vs. 3.1 RI 
episodes in the first and 1.9 vs. 3.2 episodes in the second year of life, 
respectively) (Chonmaitree et al. 2008, Gruber et al. 2008). Late day care 
attendance due to 18 months of fully paid parental leave in Estonia is one of the 
most obvious contributing factors. Attendance of day care has been identified as 
a significant risk factor for RI in several studies regardless of the day care 
setting, size of the day care group, or the number of hours spent in day care 
(Marbury et al. 1997, Gruber et al. 2008). In the present study the mean age of 
day care entry was 22.7 months in VLGA and 20.4 months in FT infants and 
only one child in both groups attended day care at the age of 12 months. In 
contrast, in the Netherlands, 66% of 12 months old children attended day care 
(van Putte-Katier et al. 2012). Another factor in the low rate of RI that should 
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be noted is retrospective design of parental interviews, which may potentially 
miss some mild cases of RI and thus lead to the under-reporting of RI. 
 
 
7.3.2. Wheezing  
Compared with FT, VLGA infants had, due to RI, more wheezing episodes 
including RW. Furthermore, those born at 22–27 GW had more RW than those 
born at 28–31 GW (Table 20). The presence of BPD was a significant risk 
factor for wheezing among VLGA infants. VLGA infants with BPD as com-
pared to those without BPD experienced more frequently wheezing (55 vs. 
29%; OR 3.08; 95% CI 1.34–7.04) as well as RW (28 vs. 10%; 3.31; 1.22–8.97) 
whereas there was no significant difference between VLGA infants without 
BPD compared with FT infants in wheezing and RW (29 vs. 21%; 1.51; 
0.872.62 and 10 vs. 5%; 2.40; 0.936.21, respectively). 
Depending on the country, study design, and year, at least one episode of 
wheezing has been described in 15–39% (Latzin et al. 2007, Garcia-Marcos et 
al. 2010) of children during the first years of life with the occurrence of RW in 
12–36% of children (Garcia-Marcos et al. 2010). In addition, wheezing and RW 
are more common in premature infants as compared with FT infants, occurring 
in up to 40–68% and 1325%, respectively (Greenough et al. 2005, Holditch-
Davis et al. 2008, Pramana et al. 2011). Similarly, a higher prevalence of 
wheezing and RW was observed in our study among VLGA infants as com-
pared with FT infants (34 vs. 21% and 14 vs. 5%, respectively). However, we 
should emphasize that the prevalence of both was in the lower end of the 
previously reported data in other countries (Greenough et al. 2005, Latzin et al. 
2007, Holditch-Davis et al. 2008, Garcia-Marcos et al. 2010, Pramana et al. 
2011). It can be suggested that a relatively low rate of RI could be just one 
reason. Although important gaps remain in the current knowledge regarding the 
role of viral RI in infancy in the inception of asthma (Rosenthal et al. 2010), 
wheezing and prematurity have been associated with respiratory morbidity in 
future life (Metsala et al. 2008). Whether a relatively low frequency of RI and 
wheezing episodes in our study cohort might predict better long-term respira-
tory health, needs further long term studies. 
 
 
7.3.3. Hospitalisation and antibiotic consumption 
During the study period there were altogether 149 hospital admissions in the 
VLGA and 69 in the FT group. The overall hospitalisation rate and that due to 
RI was significantly greater in VLGA than FT infants (Table 21). However, the 
proportion of hospital admissions due to RI among all hospitalisations was 
similar in both groups (53 vs. 57%). Of all RI episodes, 15% in VLGA and 8% 
in FT infants (p <0.001) were admitted to hospital. 
The reasons for hospitalisation due to RI differed between VLGA and FT 
infants with a higher frequency of bronchitis or bronchiolitis in VLGA infants 
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(Table 21). No differences between those born at 22–27 GW and 28–31 GW 
were observed. Among VLGA infants, the hospitalisation rate was greater in 
those with BPD compared to those without BPD (55 vs. 28%; OR 3.20; 95% CI 
1.40–7.33) whereas the hospitalisation rate was also greater in VLGA infants 
without BPD compared to FT infants (28 vs. 18%; 1.79; 1.023.17). Only one 
infant in the VLGA group was admitted to the paediatric intensive care unit due 
to RI. 
Despite the similar frequencies of RI, the hospitalisation rates were signi-
ficantly higher in VLGA, suggesting at least in part a more severe disease in 
VLGA than FT infants. Significant countrywide differences reported in hospita-
lisation rates might reflect variations in patient management with different 
thresholds for hospitalisation. In terms of VLGA infants, our hospitalisation 
rates were well in line with those in other countries. In the first two years of life 
33% of VLGA, 55% of the ones with BPD and 28% of the ones without, and 
18% of FT infants were admitted to hospital due to RI at least once in Estonia. 
In a French study of infants born prior to 29 GW, 47% were readmitted at least 
once within the first 9 months of life and the re-hospitalisation rate was twice as 
high for children who had had chronic lung disease (Lamarche-Vadel et al. 
2004). Similarly, in a study from the United States (Smith et al. 2004) in the 
cohort of infants born before 33 GW, 49% of infants with BPD were re-hospi-
talised in the first year of life, more than twice the rate of re-hospitalisation of 
the non-BPD population, which was 23%. However, much lower rates of 
hospitalisations have been reported for preterm as well as for FT infants in 
Switzerland: 25% of VPT infants with median GA of 28.7 weeks and only 1.5% 
of infants born at term had to be hospitalised for respiratory problems in their 
first year of life (Latzin et al. 2007, Pramana et al. 2011). 
The odds of receiving antibiotics due to RI were 2.1 times greater for VLGA 
as compared with FT infants (Table 21). Again, VLGA infants with BPD re-
ceived antibiotics more often than those without BPD (83 vs. 60%; OR 3.26; 
95% CI 1.17–9.12) whereas there was no significant difference in VLGA in-
fants without BPD compared with FT infants (60 vs. 49%; 1.53; 0.95–2.46). 
Routine antibiotic use for viral RIs is not recommended in evidence-based 
clinical practice guidelines (Wong et al. 2006). Nevertheless, despite the rarity 
of serious bacterial infections, antibiotics are frequently used in children youn-
ger than 24 months (Adcock et al. 1998). In the present study we noted that 
antibiotic consumption during RI was relatively high, especially in VLGA in-
fants. These findings likely reflect the cautious approach of paediatricians and 
family doctors in treating RI during the first years of life. On the other hand, 
diagnostic limitations and lack of rapid tests for distinguishing between 
bacterial and viral RI may also play a role, at least in the initiation of empiric 
therapy. 
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7.3.4. Risk factors for recurrent respiratory infections and adverse 
outcomes of respiratory infections 
The associations between the risk factors and unfavourable outcomes of RI as 
derived from the multiple logistic regression models are shown in Table 22. No 
associations were found between any of the investigated risk factors and the 
occurrence of recurrent RI. In the multiple analyses of the whole study 
population including both VLGA and FT infants, maternal higher education was 
protective against wheezing and male gender as well as the presence of BPD 
promoted wheezing whereas only BPD was associated with RW. In multiple 
analysis of the VLGA group, GA (as a continuous variable) was not associated 
with wheezing or RW, whereas BPD was a significant risk factor for wheezing 
(OR 3.17; 95% CI 1.36–7.41) as well as for RW (4.96; 1.46–16.83). Male 
gender, prematurity, and BPD were independent risk factors for hospitalisation 
in the whole study cohort and again, in the VLGA group, GA (as a continuous 
variable) and male gender were not associated with hospitalisations due to RI, 
whereas BPD appeared to be a significant risk factor (3.20; 1.40–7.33). 
A vast number of risk factors (e.g. abnormal early lung function including 
BPD, day care attendance, male gender, parental smoking, family size, exposure 
to home dampness and mould, and prematurity) have been associated with 
recurrent RI, wheezing, and hospitalisations due to RI in the first years of life 
(Latzin et al. 2007, de Martino and Ballotti 2007, Gruber et al. 2008, Holditch-
Davis et al. 2008, Garcia-Marcos et al. 2010, de Pramana et al. 2011, van Putte-
Katier et al. 2012). Although the protective role of breastfeeding and maternal 
university education against recurrent RI and infant wheezing is well known in 
developing countries, the effect in more developed countries is less clear (de 
Martino and Ballotti 2007, Garcia-Marcos et al. 2010). Surprisingly, in the 
present study only four risk factors – low maternal education, male gender, pre-
maturity, and the presence of BPD – were found to be significant for unfavour-
able outcomes of RI whereas BPD was the only risk factor for all of them. 
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8. GENERAL DISCUSSION 
8.1. The outcome of very preterm infants  
as an indicator of quality of care in Estonia 
Study II is the first nationwide study from an Eastern European country that 
reflects the recent changes in patient characteristics, management, morbidity, and 
outcome until death or discharge home for VLGA infants. The results of the study 
show an improvement in perinatal management of VLGA infants: a higher pro-
portion of infants were born by caesarean section and received antenatal corti-
costeroids, maternal antibiotics, and/or surfactant therapy, whereas a lower pro-
portion of infants had an Apgar score <5 at 1 minute. The most important finding 
is the improved survival of VLGA infants, whereas morbidity at discharge and the 
length of hospital stay remained unchanged. Furthermore, the improved survival 
was achieved in conjunction with less invasive neonatal treatment: a lower 
proportion of VLGA infants was intubated after birth, treated with antibiotics or 
inotropes, or mechanically ventilated, and ventilation was of shorter duration. It is 
noteworthy that these improvements of care were achieved with relatively limited 
resources. In 2006, healthcare expenditure in Estonia in terms of purchasing power 
parity per capita, had increased to US$ 996 but still remained three times lower 
than the figure for states that were members of the European Union before 2004 
(World Health Organization Regional Office for Europe 2007). 
 
Survival 
Over the study periods, the rate of survival until discharge increased significant-
ly, up to 85% among all VPT live births in Estonia. This may be attributable to 
a principle of antenatal regionalisation, proactive perinatal management, active 
admittance of infants for care, and an established national consensus on aims of 
treatment, as well as to improvements in technology and expertise. The 51% 
survival rate achieved for infants born at 22–25 GW in the later cohort 
20072008 is good when compared with similar published population-based 
studies, which have reported rates between 31% and 40% (Table 7), although 
Nordic countries report higher rates (Markestad et al. 2005, Fellman et al. 
2009). The study demonstrates that achieved survival rates in Estonia are com-
parable to those obtained in developed countries (Tables 6 and 7). 
 
Regionalisation and onsite neonatal units 
Healthcare and health-system factors play a role in the outcome of VLGA 
infants more generally; for example, Marlow et al. (Marlow et al. 2014) have 
now published data on the outcome of all 2,460 EPT births in England from the 
cohort born in 2006. The study showed that, first, with antenatal transfer of 
mother to a tertiary centre there were fewer intrapartum or labour ward deaths. 
Second, where infants remained behind in lower level services, overall 
mortality proved to be higher than for those infants in tertiary level services. 
And finally, tertiary level services with the highest activity had fewer deaths 
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than tertiary services with a lower workload of EPT infants. Also, a much-
quoted German study (Poets et al. 2004) concentrated on babies born in units 
with a NICU versus those born in units without a NICU and showed better 
outcomes in the former category. Poets and his colleagues (Poets et al. 2004) 
recommended that, to achieve best outcomes, neonatal units should look after at 
least 36 to 50 VLBW infants annually. Additionally, the separation of VPT in-
fants from their mothers directly after birth could bring along many unfavour-
able consequences (Flacking 2012).  
Therefore, one of the indicators of the quality of care of VPT infants is the 
proportion of VPT births delivered in maternity units with an onsite NICU. The 
organisation of care for these infants varies greatly in Europe (Van Reempts et 
al. 2007). According to the data from the EURO-PERISTAT Project in 2010, 
there was a wide variation in the proportion of VPT babies born in the highest 
level of care. This percentage ranged from about 20 to 100%, whereas only 
22.5% of all VPT infants were born at the highest level of care in Estonia 
(EURO-PERISTAT Project 2010). The principal difficulty in interpreting this 
indicator is the absence of consensus definition of an “onsite NICU” and levels 
of neonatal care. For instance, in the EURO-PERISTAT Project these data were 
collected and presented on local classifications of units. Only 16 from 29 
participating countries in the project were able to provide some data about this 
indicator (EURO-PERISTAT Project 2010). While it is easy to agree on what 
constitutes a tertiary or regional centre with full neonatal intensive care faci-
lities, many countries, including Estonia, have intermediate levels of care that 
provide care to many, but not all, high-risk infants. 
In the present study, 90% of VPT infants were born in 20072008 at tertiary 
level maternity hospitals, which allowed them to receive optimal obstetrical 
care. However, higher rates of antenatal transfers have been reported in Norway 
(Markestad et al. 2005) and Portugal (Neto 2006). A high degree of centrali-
sation of VPT births in Estonia may result in lower effectiveness because of the 
necessity for postnatal transport of VPT newborns. Almost half of the VLGA 
infants in Studies I and II were transferred postnatally to the regional children’s 
hospitals during the first hour of life and only a quarter of infants were cared for 
at least first 48 hours of life in the NICUs of the tertiary level maternity 
hospitals. The absence of onsite neonatal units which provide full intensive 
care, including MV, and the disunity of the higher level neonatal care can be 
considered to be a weakness in the delivery of perinatal care in Estonia. 
Nonetheless, drawing practical conclusions from the published data about 
the effectiveness of perinatal regionalisation (Lasswell et al. 2010), namely to 
rigorously centralise perinatal care, meets resistance abroad (Poets 2014) as 
well as in Estonia. A mixture of hurt professional bride and a struggle for 
market share, that means economic rather than quality-related reasons could be 
the most obvious reasons for this resistance (Poets 2014). In Finland, for 
example, a country with an area nine times and with a population five times 
than of Estonia, provision of the highest level neonatal care is concentrated to 
only five centres, with many patients having long distances to cover (Lehtonen 
88 
et al. 2011). In contrast, in Estonia with a much lower annual number of VPT 
births, VPT infants are cared for in seven units with different levels of neonatal 
intensive care. Another good example beside Finland is Portugal, probably the 
European country that has made the largest step forward in reducing infant 
mortality and reorganising perinatal care (Neto 2006). 
 
Proactive perinatal management 
A study from Sweden showed that a proactive perinatal strategy increases the 
number of live births and improves the postnatal condition and survival of EPT 
infants without an increase in morbidity (Hakansson et al. 2004). In Estonia, a 
significant improvement in the administration of antenatal steroids, antibiotics, 
and delivery by caesarean section was noticed for births at 26–31 GW but not at 
<26 GW. It could be speculated that more proactive obstetrical management 
could improve the outcome, at least for infants born at 24–25 GW. An active 
approach by paediatricians resulted in a higher frequency of admittance for care 
and in a trend towards better survival of infants born before 26 GW in 2007–
2008 as compared with 2002–2003. 
 
Neonatal morbidity 
VPT infants with major neonatal morbidities have an increased risk of adverse 
long-term outcome. Brain injury, BPD, severe ROP, neonatal sepsis, and NEC 
have been shown to be predictive of poor long-term outcome (Schmidt et al. 
2003, Bassler et al. 2009). Thus, all of these conditions were included in the 
analysis of morbidity-free survival in the present study. Overall, 42% of VLGA 
infants who were born in 20022003 and 44% of those born in 2007–2008 in 
Estonia survived until discharge without major early morbidities. 
The short-term morbidity rates for VPT infants in the current study were 
higher than in other reports, especially the rate of severe PIVH, ROP, and NEC 
(Darlow et al. 2003, Vanhaesebrouck et al. 2004, Markestad et al. 2005, 
Tommiska et al. 2007, Fischer et al. 2009, EXPRESS 2010, Murphy et al. 2010, 
Zeitlin et al. 2010a) (Tables 6 and 7). Part of this difference can be explained by 
antenatal characteristics, because the incidence of prolonged PPROM was 
higher and the use of maternal antibiotics and antenatal corticosteroids lower in 
our cohorts than in those reported by others (EXPRESS 2010, Murphy et al. 
2010, Stoll et al. 2010). The high incidence of PIVH, which was found to be the 
main risk factor for death as well as for all studied unfavourable neuro-
developmental outcomes, can be related partly to transport during the early 
postnatal period (Palmer et al. 2005, Mohamed et al. 2010). The significant 
decrease in PIVH grade 3–4 among the survivors of birth at 22–25 GW between 
2002–2003 and 2007–2008 can be explained by the trend to withdraw treatment 
from VLGA infants with confirmed PIVH grade 4. The most striking difference 
compared to the reports from high income countries, which was seen in the 
incidence of ROP, might in part be explained by the absence of national 
guidelines for oxygen therapy during the study period, as changes in oxygen 
supplementation can decrease the incidence of ROP (Sears et al. 2009). 
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The most immature infants accounted for most of the difference in morbidity 
with the previously reported studies (Table 7), which suggests a need for 
continued attention to the quality of care and reinforcement of evidence-based 
guidelines for this group. 
 
Two-year outcome 
In Study III, the national cohort of VLGA infants showed impairments in cogni-
tive and language development, as well as in fine and gross motor functions, 
when compared with the FT control group, whereas 11% of VLGA infants had 
CP and 12% had NDI. Growth failure was also a significant problem among 
VLGA infants. Among all domains studied, the main risk factor for an adverse 
outcome was the existence of severe neonatal cerebral lesions. 
The higher prevalence of CP found in the present study (90.9 per 1,000 live 
births) than in Western Europe in 1995 (58.0 per 1,000 live births) (Platt et al. 
2007) can only partly be explained by a lower level of experience in Estonia as 
compared with Western Europe in taking care of infants at the borderline of 
viability, because 65% of infants with CP were born at 28 to 31 GW. The other 
possible explanations for the higher rate of CP in our population are the short 
study period, different perinatal characteristics, and the need for postnatal 
transport of infants in Estonia. The latter has been shown to be associated with 
an increased risk of PIVH (Mohamed and Aly 2010), which in turn was the 
main risk factor for CP and other adverse outcomes in the present study. 
Direct comparisons with various studies of the cognitive impairment of 
VLGA infants are difficult to perform because the inclusion criteria, assessment 
tests, and definitions used differ among studies. When reporting developmental 
outcomes, it is critical to include the whole population as the mean scores will 
be affected by the exclusion of children who function below the lower limit of 
the test. For example, with the age banding used in the 30 month assessment as 
part of the EPICURE study of 283 children of 25 GW or less (Wood et al. 
2000), 33 children (11.7%) had scores lower than 50. Without this group, the 
mean (SD) BSID-II MDI of these was 84 (12) or 1 SD below the standardi-
sation mean. Nominally assigning a score of 40 to the excluded children 
brought this down to 77. Additionally it should be noted that in the present 
study, for the FT control infants, the means of the scaled composite scores and 
subtest scores by the BSID-III were comparable to (Bode et al. 2009) or lower 
(Anderson et al. 2010, Moore et al. 2012, Serenius et al. 2013) than those 
reported previously. 
Nonetheless, it can be cautiously concluded, that when compared with pre-
viously reported studies (Tables 13 and 14), the VLGA population of the pre-
sent study, which was outborn and included infants with congenital malfor-
mations as well as infants who functioned below the lower limit of the BSID-
III, had a comparable or worse (Bode et al. 2009, Anderson et al. 2010, Munck 
et al. 2010, Moore et al. 2012, Voigt et al. 2012, Serenius et al. 2013) but still 
satisfactory outcome, despite the recent argument that the BSID-III unde-
restimates developmental delay (Anderson et al. 2010, Moore et al. 2012). The 
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proportion of infants with NDI was in accordance with recent studies (Bode et 
al. 2009, Munck et al. 2010). As a whole, the 2-year cognitive outcome results 
reflect a satisfactory level of quality of care for VPT infants in Estonia. 
 
Availability, effectiveness, and efficiency of neonatal care in Estonia 
Availability of neonatal intensive care for VLGA infants in the present studies 
can be determined, firstly, by the proportions of infants offered intensive care, 
and secondly, by the proportion of infants born at the third level maternity 
hospitals. The proportions of newborns offered intensive care increased signifi-
cantly over time from 20022003 to 20072008 in Estonia. The decision to 
offer intensive care to ELGA/VLGA live births largely reflects paediatric 
decision-making, although obstetric management sometimes takes precedence, 
particularly if a decision has been reached not to offer intensive care already 
before birth. Not all ELGA infants will benefit from intensive care; those with 
lethal malformations and those of extreme immaturity are some examples. None 
of these infants were excluded from the present studies. Hence, 100% of ELGA 
infants will never be offered intensive care. However, in the Estonian cohort of 
VLGA infants born in 20072008, 98% of infants were admitted to the neonatal 
intensive care, so there is no opportunity for the rate of offered intensive care to 
increase. On the contrary, for infants born before 24 GW, the survival until 
discharge was less than 50% and the adverse outcome at the CA of 2 years was 
80%. The intensive treatment for babies born at 2223 GW might not be appro-
priate in Estonia and health professionals should discuss with the parents the 
provision of only palliative care for these most immature infants. 
The proportion of VLGA infants born outside tertiary level maternity hospi-
tals was relatively low in Estonia, 13 % in 20022003 and 10% 20072008. 
However, infants born at local hospitals had significantly lower scores on 
BSID-III cognitive and motor composite scores at 2 years of CA compared to 
infants born at tertiary maternity hospitals. These disadvantages emphasise the 
need for VLGA infants to be born at tertiary level maternity hospitals in Esto-
nia. Nevertheless, as it has been discussed in the section of “Regionalisation and 
onsite neonatal units”, regionalisation in Estonia may result in lower effective-
ness because of the necessity for postnatal transport. We could not analyse the 
impact of early postnatal transfers in our study cohorts as none of the infants 
requiring the highest level of care with MV were cared for in the tertiary level 
maternity hospitals. Nevertheless, we suggest that one way to improve 
morbidity-free survival rates in Estonia is to establish perinatal centres with on-
site neonatal units with full intensive care, including MV and neonatal surgery. 
In the framework of the present studies, the effectiveness of perinatal and 
neonatal care can be evaluated only through the changes in the short-term 
outcome over the two studied periods 20022003 and 20072008 as the long-
term outcome was not studied over time. In Estonia, the survival rate for VLGA 
infants until discharge, which is a measure of the effectiveness of neonatal 
intensive care within a geographical region, increased significantly. The gain in 
survival was similar for infants born before 26 GW and for those born at 26 
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31 GW. Morbidity-free survival and the incidence of major neonatal morbi-
dities, predicting poor neurodevelopmental outcome, was not significantly 
different between the two studied cohorts, except for a decrease in PIVH grade 
3–4 in the cohort born in 2007–2008. On the other hand, it is noteworthy that 
survival until discharge increased without concomitant increases in neonatal 
morbidity and the length of hospital stay. Nevertheless, since the rates of neo-
natal morbidities and neurosensory impairment at 2 years of CA were clearly 
too high, and as mortality rates have fallen, the greatest challenge for neonatal 
services in Estonia is to improve the outcomes of neonatal intensive care by 
reducing the prevalence of major early morbidities for VLGA infants. 
Efficiency of neonatal intensive care has not been studied in Estonia and 
should be a key priority to research in the future. 
 
 
 
8.2. Current position of routine data collection of 
outcome for very preterm infants in Estonia 
The present studies highlight the importance of establishing nationwide datasets 
in Estonia for collection of perinatal and neonatal data until hospital discharge 
and follow-up data at 2 years of CA for VLGA infants. 
After the pilot-period in 20072008, the national neonatal research register 
called “Vastsündinu tervise andmekogu” was not permitted to continue by the 
Estonian Data Inspectorate. Furthermore, the neonatal research register was 
held by the enthusiasm of physicians and no national financial support was 
found to continue with the dataset. Estonian Medical Birth Registry has col-
lected data about all births in Estonia since 1992. However, the register is 
designed to measure fertility and it collects principal data until the end of the 
early neonatal period. Still in 2014, there are no national datasets specifically 
designed for collection of neonatal data until hospital discharge and follow-up 
data for VLGA infants in Estonia; none of the units is participating in the 
international neonatal networks. However, Estonia is participating with a 12-
month national cohort of VLGA births from 2011–2012 in the project of 
Effective Perinatal Intensive Care in Europe to explore the outcome of VLGA 
infants and the use of evidence based practices for the care of VLGA infants 
during the recent years (EPICE project 2014). 
Monitoring of variations in mortality and morbidity rates for VLGA infants 
is important as they indicate changes in practice that may improve outcome. In 
addition, the information on late morbidity in survivors of neonatal intensive 
care is needed for several target groups: 1) parents, to understand the possible 
consequences of survival of their baby and accept informed decisions about 
their child’s care; 2) the clinical team, for sharing with parents, evaluating their 
service, and research; 3) commissioners of neonatal care and other services for 
children so that they can make informed decisions and plans; and 4) general 
public so they can take part in an informed debate on priorities in healthcare 
(Rattihalli et al. 2011). 
92 
8.3. Impact of the studies on follow-up of very preterm 
infants in clinical practice in Estonia 
Neurologic sequelae and developmental disorders are among the complications 
with the greatest influence on long-term quality of life. Screening for these 
developmental anomalies must therefore be a major objective in the follow-up 
of VPT infants, and care after discharge is now considered a critical part of the 
neonatal intensive care service. However, these follow-up programmes are 
costly, time-consuming, and might cause unnecessary anxiety to parents and 
children. Therefore, there is a need to identify precisely which children have to 
be included in such programmes.  
In the Study III, more advanced GA correlated with better composite neuro-
development but not with each individual outcome studied. EPT infants 
comprised only a minority of infants with growth failure, CP, or other problems 
as cognitive and language developmental delay. In addition, even infants who 
were free of neurosensory impairment had significantly worse scores in cogni-
tive, language, and motor development than FT control infants. As a conse-
quence, in response to the understandable concern about EPT infants, the results 
support the recommendation to monitor all VLGA infants in clinical practice, at 
least in Estonia.  
Despite the absence of national follow-up register for VPT infants in Esto-
nia, these infants are followed in everyday clinical practice until the CA of 2 
years according to national follow-up guidelines (Toome et al. 2008). Since 
2009, the BSID-III has been used in the routine clinical follow-up programme 
of high-risk, including VLGA, infants to assess their cognitive, language, and 
motor development. 
In the Study IV, a similar frequency of RI among VLGA and FT infants 
during the first two years of life was observed. On closer examination, however, 
a greater frequency of RI among those born at 22–27 GW as compared with the 
other GA categories was observed in the first year of life. Despite the similar 
rate of RI in both groups, VLGA infants experienced more wheezing and RW 
episodes, especially those born before 28 GW and/or diagnosed with BPD. 
Moreover, VLGA infants also required hospitalisations and received antibiotics 
due to RI more frequently. However, there was no significant difference 
between VLGA infants without BPD compared with FT infants in wheezing 
and RW. In multiple analyses it was not prematurity in itself but the presence of 
BPD that appeared to be the most important independent risk factor for 
unfavourable outcomes of RI. 
Consequently, from a clinical point of view the results of Study IV suggest a 
tailored approach when planning hospital discharge of VLGA infants. Special 
attention should be targeted to the parents of infants with BPD or born before 
28 GW in counselling to limit the exposure of their children to respiratory 
viruses and environmental risk factors. Additionally, the resources in preventing 
respiratory viruses should be allocated, first of all, to VLGA infants with BPD 
and to those born before 28 GW.  
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8.4. Suggestions for future improvement in the quality  
of care for very preterm infants in Estonia 
The challenge for perinatal services in Estonia is to decrease long-term disabi-
lity in VPT infants without compromising their survival. Given that the rate of 
VPT live births in Estonia is within the range of other European countries, and 
that improvement of the socio-environmental milieu requires time, there is an 
urgent need for a reduction in neonatal morbidity in order to improve the long-
term outlook for VLGA infants. 
Focusing on the improvement of outcome, we propose the following ap-
proaches to increase morbidity-free survival of VLGA infants in Estonia. 
First is the ongoing implementation of the evidence-based national guide-
lines to unify the policies of different units. Following completion of the present 
studies, hospitals in Estonia have already implemented guidelines for neonatal 
resuscitation, oxygen therapy with saturation targets, introduction of early 
CPAP in the delivery room, etc. Nevertheless, these guidelines have to be 
unified on the national level. In 2014, the Estonian Ministry of Social Affairs 
and the Estonian Perinatal Society called together a team of specialists to 
establish national guidelines with respect to the management of the VPT deli-
very and birth in the country.  
Second, the official levels of perinatal and neonatal care (Riigi Teataja 
2004) in Estonia should be re-evaluated and maximally two perinatal centres 
should be established that offer all the services of third level antenatal and 
perinatal care and have onsite neonatal units to provide full intensive care. This 
will reduce the need for postnatal transfers and will improve the collaboration 
of antenatal staff with neonatologists with regard to the timing of birth and 
appropriate perinatal care. Introducing a better regionalisation of perinatal care 
requires binding rules and regulations. This is a task for regulatory bodies, for 
example, the government, not for obstetricians or neonatologists (Poets 2014).  
Third approach is to establish the ongoing surveillance of outcomes and 
iatrogenic factors that might have detrimental effects on the health of VPT in-
fants. For example to incorporate an additional data file with important 
variables on all VPT infants to the Estonian Medical Birth Registry and to 
collect the data until the infant's PMA of 44 weeks' gestation. Furthermore, it is 
unarguable that each unit that delivers VPT babies must audit short-term and 
long-term outcomes and be ready to produce them for benchmarking. The 
general public require to be informed about the mortality and morbidity figures 
for the units within their region. Audit must be robust and universal. All centres 
should be benchmarking their data on the national level as well as with some 
system which has been extensively validated, for example, the Vermont Oxford 
Network (Laing 2014). 
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8.5. Strengths and limitations of the studies 
Since the introduction of antenatal steroids and postnatal surfactant therapy in 
perinatal treatment of VPT infants, studies from developed countries have 
presented population-based outcomes for EPT and VPT infants (Tommiska et 
al. 2001, Darlow et al. 2003, Larroque et al. 2004, Vanhaesebrouck et al. 2004, 
Markestad et al. 2005, Tommiska et al. 2007, Fischer et al. 2009, EXPRESS 
GROUP 2010, Murphy et al. 2010, Zeitlin et al. 2010, Rüegger et al. 2012). 
However, although some data are available (Gadzinowski et al. 2010), no 
nationwide studies have been published from Eastern European countries, 
which have more limited resources and less experience in the care of EPT in-
fants than high income countries. The latter ascribe the importance to the 
present studies, which to our knowledge, are the first nationwide short-term and 
long-term outcome studies of VLGA infants from an Eastern European country. 
Our epidemiological data and the insight into perinatal services in Estonia will 
be useful for other middle income countries for comparison. 
The main strength of our studies is the nationwide population-based design 
that gives a complete picture of the outcome for all VPT births during the study 
periods and thus ensures the provision of detailed information, first, for use in 
prenatal counselling and decision-making by physicians and families, and 
second, for benchmarking the quality of care of VPT births in Estonia. Additio-
nally, the use of GA as an inclusion criterion enabled a large group of VPT 
infants to be studied and reduced the proportion of infants who were small for 
their GA. The other strengths of the studies are the use of standardised methods 
for follow-up, the inclusion of an age, gender, and geographic location matched 
control group of FT infants in Studies III and IV, and the attainment of follow-
up rates that were close to 100%. The high follow-up rate eliminates potential 
bias in the interpretation of the outcomes caused by the possible neuro-
developmental morbidity among infants lost to follow-up. 
We acknowledge some limitations of the study, which include:1) the retro-
spective nature of the data that relate to the earlier cohort of VLGA infants born 
in 20022003 in Study II; 2) a relatively small study cohort in subgroups of 
EPT infants particularly in Studies III and IV; 3) the short-term outcome for 
VLGA infants was analysed from live-born infants whereas to benchmark 
perinatal services more precisely, there is a need to evaluate all stillbirths where 
the foetus is alive at the onset of the delivery; 4) the BSID-III had not been 
standardised previously for use in Estonia; 5) CP was chosen as an index of 
long-term outcome, which could lead to an underestimation of motor disability; 
6) the retrospective design of parental interviews in Study IV and not collecting 
data about relevant childhood immunisations and common environmental risk 
factors for RI, like paternal smoking and presence of pets at home; and 7) the 
low statistical power using multiple risk-adjustment methods based on a single 
year to detect predictors for unfavourable outcomes. However, we believe that 
the abovementioned limitations did not preclude us from drawing adequate 
conclusions. 
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8.6. Suggestions for future research 
The present studies raise several questions for future research: 
 Neonatal intensive care for VLGA infants in Estonia should be re-evaluated 
at intervals in the future to ensure that its effectiveness and availability are 
maintained. Beside survival rates, morbidity and length of hospital stay until 
discharge and neurosensory impairment and developmental disability rates at 
the CA of 2 years, the quality-adjusted survival rate, another measure of the 
increasing effectiveness of neonatal intensive care within a geographical 
region, should be evaluated over time. 
 One tool that is being used to improve complex medical care processes is 
comparing the performances of different hospitals and learning from the 
better performing centres. Therefore, centre-differences in care and outcome 
should also be evaluated in Estonia. 
 The efficiency of perinatal and neonatal care as well as of follow-up pro-
grammes for VPT infants has never been evaluated in Estonia. Since there 
have been large increases in effectiveness during the last decade, one sug-
gestion for future research is to determine the efficiency as well as the 
changes in efficiency of neonatal intensive care for VPT infants in Estonia. 
 In the present study, the outcome for VLGA infants was evaluated until the 
CA of 2 years. However, the predictive validity of developmental testing at 2 
years of age for cognitive, behavioural, and learning problems might be poor 
(Hack et al. 2005b). Whilst the authors of early studies sought to catalogue 
the severe neurological and sensory disabilities associated with VPT birth, 
recent research has highlighted a range of more subtle deficits and has 
shown that the nature of impairment may be changing (Aylward 2003). 
Cognitive and behavioural problems are among the most common adverse 
outcomes and such “higher prevalence/lower severity” impairments are more 
evident at school age, even in those who are free of neurosensory impair-
ments. To provide a more complete picture of longer-term effects on the 
survivors, follow-up studies for children born VPT through the school years 
are needed in Estonia. 
 The studied cohorts of VLGA infants born in 20022003 and 20072008 are 
the first ones with systematically collected perinatal and neonatal data in 
Estonia. The latter offers an opportunity to study different aspects of as-
sociations of prognostic factors and health outcomes beside neurosensory 
and developmental impairment.  
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9. CONCLUSIONS 
1. The nationwide studies of short-term outcome for VLGA infants showed 
that: 
1.1. The rate of VLGA births in Estonia during the studied periods (11.3 
per 1,000 live births in 20022003 vs. 10.2 in 20072008) has re-
mained unchanged, whereas the outcome for VLGA infants has im-
proved since 2002. 
1.2. With proactive perinatal management, active admission of VLGA 
infants to intensive care, and less invasive neonatal care, survival for 
VLGA live births until discharge increased significantly from 78% in 
20022003 up to 85% in 20072008 without concomitant increases in 
neonatal morbidity and the length of hospital stay. 
1.3. During the later study period 2007–2008, there were centre differences 
in the early neonatal management of VLGA infants. 
 
2. The nationwide follow-up studies for VLGA infants at the CA of 2 years 
showed that: 
2.1. No impairment was found in 60% of the VLGA infants. NDI was 
noted in 12% of VLGA infants, with 8% of the infants affected by CP 
without independent walking, 5% with cognitive delay, 10% with 
language delay, and 1% with hearing impairment. 
2.2. In all domains studied regarding neurodevelopment and growth, ad-
verse conditions were more prevalent among VLGA infants than 
among the FT control group. The differences between VLGA and FT 
infants in terms of the mean Cognitive, Language, and Motor Com-
posite Scores assessed using the BSID-III scales were in excess of  
0.5 SD. Among all the VLGA infants, 31% were below the 10th per-
centile of expected bodyweight.  
2.3. The frequency of RI during the first two years of life, in general, was 
similar among VLGA and FT infants, except for those born at 22 to  
27 GW. Nevertheless, VLGA infants, especially these born before  
28 GW and/or diagnosed with BPD, had more wheezing episodes and 
hospitalisations due to RI than their FT counterparts. 
 
3. In the present studies, seven prognostic factors for death until hospital 
discharge and for the presence of growth failure and an adverse neuro-
developmental outcome at the CA of 2 years as well as for unfavourable 
outcomes of RI were found: 
3.1. GA and male gender were the only significant neonatal characteristics 
for adverse outcome (GA for death, bodyweight 10th percentile, and 
NDI, and male gender for language development delay). 
3.2. From perinatal characteristics, low Apgar score at birth was a risk 
factor for death and antenatal corticosteroids were protective against 
growth failure. 
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3.3. The most significant risk factor of different adverse outcomes found 
was the presence of major neonatal morbidities. Severe PIVH and/or 
PVL were associated with death, bodyweight 10th percentile, and all 
studied adverse neurodevelopmental outcomes, whereas BPD was 
associated with bodyweight 10th percentile and all unfavourable out-
comes of RI. NEC was a significant risk factor for cognitive develop-
ment delay. 
 
4. From a clinical point of view the results of the studies suggest two main re-
commendations: 
4.1. Not only ELGA, but all VLGA infants should be monitored in a 
clinical practice at least the first two years of life. The recommendation 
is based on the following: 1) in the follow-up study regarding growth 
and neurodevelopmental outcome, GA did not correlate with each 
individual outcome studied among VLGA infants; 2) ELGA infants 
comprised only a minority of infants with growth failure, CP, and 
developmental problems; and 3) even infants who were free of neuro-
sensory impairment had significantly worse scores in cognitive, lan-
guage, and motor development than infants from the FT control group. 
4.2. Regarding the prevention of RI among VLGA infants, the results 
suggest a tailored approach when planning hospital discharge of 
VLGA infants. Special attention should be targeted to the parents of 
infants with BPD or born before 28 GW in counselling to limit the 
exposure of their children to respiratory viruses and environmental risk 
factors. Additionally, the resources in preventing respiratory viruses 
should be allocated, first of all, to VLGA infants with BPD and to 
those born before 28 GW. 
 
5. As a whole, the results reflect a satisfactory level of quality of care for 
VLGA infants in Estonia. Despite the improved survival of VLGA infants, 
the morbidity rates of infants were similar or higher when compared with 
comparable data from high-income countries. Consequently, the greatest 
challenge for perinatal and neonatal services in Estonia is to improve the 
long-term outcome for VLGA infants by reducing the prevalence of major 
early morbidities. The main requirements for that in Estonia are the ongoing 
implementation of evidence-based practices, reorganisation of perinatal care 
by establishing two perinatal centres that offer tertiary level neonatal inten-
sive care on site, and ongoing surveillance of iatrogenic factors that might 
have detrimental effects on the health of VLGA infants.  
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11. SUMMARY IN ESTONIAN 
Väga väikese gestatsioonivanusega enneaegsed lapsed Eestis: 
ravitulem ja prognostilised tegurid 
Maailmas sünnib ligikaudu 11% lastest enneaegsena, enne 37 gestatsiooninäda-
la (GN) täitumist (Blencowe et al. 2012). Seejuures toimub enne 32 GN täitu-
mist e väga väikesel gestatsioonivanusel (VVGV) vaid 11,5% kõigist sündi-
dest, kuid see lastegrupp on eriti õrn ja moodustab umbes pooled vastsündinu- 
ja imikuea surmajuhtudest (EURO-PERISTAT Project 2010). Perinataalabi ja 
vastsündinute intensiivravi areng on märkimisväärselt suurendanud VVGV 
vastsündinute elulemust, kuid kaasa toonud ka laste kroonilised terviseprob-
leemid, suured ravikulud, perede häiritud psühhosotsiaalse toimetuleku ning 
lapse edasise elu jooksul kumuleeruvad ühiskonna kulutused. 
Tänapäevase meditsiiniabi põhiprintsiibiks on pakkuda kvaliteetset ravi. 
Peri- ja neonataalabi tundlikuks kvaliteediindikaatoriks on VVGV laste ravi-
tulem. Üldtunnustatult peegeldab peri- ja neonataalabi kvaliteeti VVGV enne-
aegsete laste tervis 2-aastaselt korrigeerituna enneaegsusele sünnil. Selleks 
vanuseks on enamus puuetest diagnoositavad ning lapse areng ei ole mõjutatud 
niivõrd sotsiaalsetest teguritest  nt vanemate haridusest ja sotsiaalmajandus-
likust toimetulekust  kui peri- ja neonataalperioodi ravi kvaliteedist (Lyon 
2007). Uuringutega on tõestatud erinevate neonataalsete haiguste (bronho-
pulmonaalne düsplaasia, (peri)intraventrikulaarne ajuhemorraagia, periventriku-
laarne leukomalaatsia, nekrotiseeriv enterokoliit, sepsis ja enneaegsuse retino-
paatia) põdemisel esinev risk VVGV laste hilisematele puuetele ja arengu-
häiretele (Schmidt et al. 2003, Bassler et al. 2009).  
1980.1990. aastate murrangulised  avastused olid aluseks enneaegsete vast-
sündinute tänasele intensiivravile, eelkõige antenataalne glükokortikoidravi 
laste suremuse vähendamisel ning haigestumise ennetamisel ja postnataalne 
surfaktantravi hingamishäirete ravis. 21. sajandil on tõenduspõhine VVGV vast-
sündinu vähe-invasiivne sünnijärgne ravitaktika, eriti kopsude mehaanilise 
ventilatsiooni vajaduse ennetamine (Sweet et al. 2013). Ravikvaliteedi kõrval 
mõjutab laste tervisetulemit oluliselt perinataalabi ja vastsündinute intensiivravi 
korraldus. Väga enneaegsete sünnituste koondamine III etapi ravivõimalustega 
ja piisava enneaegsete vastsündinute arvuga keskustesse vähendab laste sure-
must ja haigestumist, kusjuures mõjutavateks teguriteks peetakse nii III etapi 
keskuste kogemust kui vastsündinu sünnijärgse varase transpordi potentsiaalset 
negatiivset toimet (Rautava et al. 2007, Lasswell et al. 2010, Mohamed et al. 
2010). 
1992. aastal võeti Eestis kasutusele Maailma Terviseorganisatsiooni enne-
aegsuse kriteerium (2236 GN) ning alustati  1000 g sünnikaaluga ja enne  
28 GN täitumist sündinud laste sünni registreerimist ja ravi. Kiire tehnilise 
arengu ning teadmiste ja kogemuste täiustumise tulemusel on  1000 g sünni-
kaaluga vastsündinute varane neonataalsuremuskordaja aastatel 19922012 
vähenenud Eesti meditsiinilise sünniregistri andmetel ligi 9 korda. 1990-ndatest 
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aastatest toimib Eestis enne 34. GN toimuvate sünnituste tsentraliseerimine III 
etapi sünnitusmajadesse ning kasutusel on tänapäevased tõenduspõhised ravi-
võtted. Eestis puuduvad aga perinataalsed keskused, mistõttu III astme 
intensiivravile ja/või pikemale haiglaravile kuuluvad vastsündinud tuleb 
transportida III etapi sünnitusmajadest kahe lastehaigla lasteintensiivravi või 
vastsündinute osakonda. 
 
 
Uurimistöö eesmärgid 
 
Perinataalabi ja vastsündinute intensiivravi kvaliteedi ning korralduse hinda-
misel peetakse ülioluliseks rahvastikupõhist peri- ja neonataalabi näitajate 
seiret. Eestis puudusid edasivaatavalt kogutud rahvastikupõhised andmed 
VVGV vastsündinute ravitulemi kohta, mistõttu uurimistöö üldeesmärgiks oli 
kirjeldada VVGV laste ravi varast ja hilist tulemit Eestis.  
Töö alaeesmärgid olid: 
1. Kirjeldada aastatel 20072008 sündinud VVGV vastsündinute varast ravi-
tulemit (intensiivravile suunamine, suremus, neonataalne haigestumine, 
ravitoimingud, haiglaravi kestus ja keskustevahelised erinevused) esmase 
haiglaravi lõpul (uuring I) ja leida muutused VVGV sündide osakaalus ning 
laste varases ravitulemis võrreldes aastatel 20022003 sündinud laste 
võrdluskohordi tulemiga (uuring II). 
2.  Kirjeldada 2007. aastal sündinud VVGV laste ravi hilistulemit enne-
aegsusele korrigeeritud 2 aasta vanuses ning võrrelda andmeid ajalisena 
sündinud ja individuaalselt sobitatud võrdluskohordi laste tulemiga (uuring 
III). 
3. Kirjeldada VVGV laste ägedat respiratoorset haigestumist kahel esimesel 
eluaastal ning võrrelda ajalisena sündinud laste haigestumisega (uuring IV). 
4. Leida riskitegurid VVGV laste surmaks ja ebasoodsaks tervisetulemiks enne-
aegsusele korrigeeritud 2 aasta vanuses (uuring II, III). 
5. Leida riskitegurid kahe esimese eluaasta ägeda respiratoorse haigestumise 
ebasoodsaks kuluks (uuring IV). 
6. Hinnata tervikuna peri- ja neonataalabi kvaliteeti Eestis ning leida teed 
ravikvaliteedi edasiseks parandamiseks. 
 
 
Patsiendid ja metoodika 
 
Käesolev uurimus oli rahvastikupõhine edasivaatav kohortuuring, mis hõlmas 
aastatel 20072008 elusalt sündinud VVGV laste kohorti ning koosnes neljast 
alauuringust. 
 
Uuring I ja II 
Varase ravitulemi hindamiseks analüüsiti 2007.2008. aastal elusalt sündinud 
360 VVGV lapse kohorti ning muutuste leidmiseks ajas võrreldi 2002.2003. 
aastal elusalt sündinud 264 VVGV lapse kohordiga. Lapsi jälgiti esmase haigla-
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ravi lõpuni, välja arvatud enneaegsuse retinopaatia diagnoosimisel, mil lapsi 
jälgiti võrkkesta täieliku vaskulariseerumiseni. 2007.2008. aasta kohordi and-
med saadi uuringuregistrist „Vastsündinute tervise andmekogu”, kuhu raviarstid 
sisestasid edasivaatavalt laste ravijuhtude andmed. Küsimustik koosnes 68 
tunnusest raseduse ja sünnituse kulu, sünni, lapse sünnijärgse transpordi, pea-
miste neonataalsete haiguste, ravitoimingute ja tulemi kohta. Andmekogu töötas 
internetipõhiselt, töös järgiti isikuandmete kaitse nõudeid ja andmekogu oli 
registreeritud Andmekaitse Inspektsioonis. Kogutavate tunnuste definitsioonid 
olid eelnevalt määratletud. Varasema kohordi laste andmed sisestati uuringu-
registrisse tagasivaatavalt. 
 
Uuring III ja IV 
2007. aastal elusalt sündinud 187 VVGV last moodustasid alakohordi, kelle ravi 
hilistulemit (uuring III) ja ägedat respiratoorset haigestumist kahel esimesel 
eluaastal (uuring IV) hinnati laste enneaegsusele korrigeeritud 2 aasta vanuses. 
Antud vanuses elus olnud 156-st lapsest osales uuringus 155 (99%), sest üks 
pere oli Eestist lahkunud. 
Laste tervisetulemit ja ägedat respiratoorset haigestumist võrreldi ajalisena  
(≥ 37 GN) sündinud laste võrdluskohordi tulemustega. Igale VVGV lapsele 
sobitati sünnitushaiglate andmebaaside alusel kaks ajalisena sündinud last 
vastavalt järgnevatele kriteeriumidele: 1) ajalised lapsed olid sündinud esimes-
tena peale VVGV lapse oodatavat sünnikuupäeva samas geograafilises piir-
konnas; 2) nad ei vajanud esimesel elunädalal ravi; ja 3) olid sobitatud VVGV 
lapse soo ja rahvusega. Kui kahest individuaalselt sobitatud ajalisest lapsest 
esimese vanemad keeldusid uuringus osalemast, siis pöörduti teise lapse 
vanemate poole. Kahel juhul ei soovinud uuringus osaleda kumbki pere. Seega 
kokku osales hilistulemi uuringutes 153 ajalisena sündinud last. Uuringust III ja 
IV ei arvatud välja oluliste kaasasündinud väärarenditega VVGV lapsi ning 
ajalisena sündinud lapsi, kellel oli diagnoositud arengut potentsiaalselt mõjutav 
haigus peale esimest elunädalat. 
Laste enneaegsusele korrigeeritud 2 aasta vanuses ( 1 kuu) kutsuti uurita-
vad järelkontrolli ühte kahest uuringukeskusest, Tallinna Lastehaiglasse või 
Tartu Ülikooli Kliinikumi lastekliinikusse. Hinnati laste somaatilist, neuro-
sensoorset ja arengulist tulemit. Laste kaalu, pikkust ja peaümbermõõtu mõõdeti 
tavapäraste mõõtmisvahenditega. Laste arengut hindas psühholoog standardi-
seeritud Bayley testi 3. versiooni abil (Bayley 2006), mille alusel saadi koond-
skoorid kognitiivsele, kõne ja motoorsele arengule ning alatesti skoorid 
retseptiivsele ja ekspressiivsele kõnele ning peen- ja jämemotoorikale. Neuro-
loogilist leidu hindas lasteneuroloog. Tserebraalparalüüs defineeriti vastavalt 
Euroopa tserebraalparalüüsi seire töögrupi klassifikatsioonile (Surveillance of 
Cerebral Palsy in Europe 2000) ning motoorse funktsiooni hindamisel kasutati 
jämemotoorika hindamise skaalat (Gross Motor Function Classification System, 
GMFCS; Palisano et al. 1997). Paralleelselt kirjeldatud meetoditega kasutati ka 
pediaatrilise insuldi tulemi mõõdikut (Paediatric Stroke Outcome Measure, 
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PSOM; de Veber et al. 2000). Andmed nägemis- ja kuulmispuude kohta saadi 
laste kliinilisel järelkontrollil teostatud uuringutest.  
Kognitiivse, kõne ja motoorse arengu mõõdukas/raske mahajäämus diag-
noositi juhul, kui vastavad koondskoorid olid  -2 SD hinnatuna Bayley testi 
järgi. Mõõdukas/raske arenguhäire defineeriti juhul, kui lapsel esines vähemalt 
üks järgnevatest kriteeriumidest: tserebraalparalüüs (GMFCS-skaala 2.5. aste), 
kognitiivse arengu mõõdukas/raske mahajäämus, kõne arengu mõõdukas/raske 
mahajäämus, raske nägemispuue ja/või raske kuulmispuue.  
Ravi ebasoodsaks hilistulemiks laste enneaegsusele korrigeeritud 2 aasta 
vanuses loeti kaalu  10 protsentiili vastavalt eesti 0–2 aastaste laste kasvukõve-
ratele ja/või tserebraalparalüüsi, kognitiivse arengu mõõduka/raske maha-
jäämuse, kõne arengu mõõduka/raske mahajäämuse ja/või mõõduka/raske 
arenguhäire  esinemist. 
Äge respiratoorne haigestumus selgitati vanemate küsitluse teel tagasivaata-
valt järelkontrolli päeval, hospitaliseerimised täpsustati haiglate andmebaasi-
dest. Ägeda respiratoorse haigestumise ebasoodsaks kuluks loeti kas ühekordse 
või korduva vilistava hingamise esinemist ja/või haiglaravi vajadust. 
Andmeanalüüs tehti programmiga Stata 12 (StataCorp LP, College Station, 
Texas). 
Uuringud kiitis heaks Tartu Ülikooli inimuuringute eetika komitee ning 
uuringus III ja IV osalenud laste vanema(te)lt võeti informeeritud nõusolek. 
 
 
Peamised tulemused 
 
VVGV enneaegsete laste varane ravitulem esmase haiglaravi lõpul 
Eestis sündis elusalt 360 VVGV last aastatel 20072008 ja 264 last aastatel 
20022003, moodustades 1,1 ja 1,0% kõikidest elussündidest (p = 0,184). 
Hilisemas perioodis oli suurem mitmikute osakaal ja emade keskmine vanus. 
Samuti oli VVGV sündide perinataalne käsitlus proaktiivsem hilisemal perioo-
dil: antenataalselt rakendati enam loote kopsude ettevalmistamist glükokorti-
koidiga (73 vs 81%; p = 0,020) ja antibakteriaalset ravi (37 vs 55%; p  0,001) 
ning oluliselt rohkem VVGV lapsi sündis keisrilõike teel (42 vs 54%; p = 
0,005). Perinataalne käsitlus oli proaktiivsem eeskätt küpsemate, 26.31. GN 
sündinud laste seas. Kaasuvalt vähenes antud gestatsioonivanuste vahemikus 
sündinud laste osakaal, kelle Apgari hinne oli 1. eluminutil väiksem kui 5. 
Mõlemal uuringuperioodil sündis Eestis ligikaudu 90% VVGV lastest III 
etapi naistekliinikus, kuid ligikaudu pooled neist vajasid esimesel elutunnil 
kohest transporti lastehaiglasse ning vaid neljandik lastest transporditi laste-
haiglasse peale 48. elutundi. 
Võrreldes varasema perioodiga 2002–2003 suunati aastatel 2007–2008 enam 
VVGV lapsi intensiivravile (94 vs 98%; p = 0,013) ning oluliselt suurenes ka 
elulejate osakaal kõigist VVGV elussündidest (78% vs 85%; p = 0,041). 
Elulemuse paranemisega ei kaasnenud hilisemaid puudeid ennustavate  neo-
nataalsete haiguste esinemise suurenemist. Aastatel 20022003 ja 20072008 
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oli ≥ II staadiumi nekrotiseerivat enterokoliiti ja positiivse verekülviga hilist 
sepsist põdenud VVGV laste osakaal vastavalt 7 vs 12% (p = 0,055) ja 23 vs 
22% (p = 0,692) elusalt sündinud VVGV lastest. Ellujäänud VVGV lastest 
põdesid antud ajaperioodidel bronhopulmonaalset düsplaasiat hapnikravi vaja-
dusega 36. postmenstruaalnädalal 20 vs 24% (p = 0,388), IIIIV astme 
(peri)intraventrikulaarset hemorraagiat 9 vs 5% (p = 0,058), IIIV astme peri-
ventrikulaarset leukomalaatsiat 7 vs 4% (p = 0,068) ja ≥ III staadiumi 
enneaegsuse retinopaatiat laserravi vajadusega 11 vs 11% (p = 0,886) lastest. 
Elulemuse suurenemine saavutati vähem invasiivse neonataalse raviga: 
hilisemas perioodis oli väiksem laste osakaal, kes vajasid esimesel elutunnil 
endotrahheaalset intubatsiooni ning kogu esmase haiglaravi jooksul inotroopset 
ravi, kopsude mehaanilist ventilatsiooni ja/või antibakteriaalset ravi. Samuti  
lühenes kopsude mehaanilise ventilatsiooni ja antibakteriaalse ravi kestus. 
VVGV laste varases sünnijärgses ravitaktikas ilmnesid aastatel 20072008 olu-
lised keskustevahelised erinevused. Nimelt kasutati ühes kolmest III astme 
naistekliinikus sünnijärgsete hingamishäirete ravis oluliselt enam pideva posi-
tiivse rõhu varast rakendamist, millega kaasus kopsude ventilatsiooni vajaduse 
oluline vähenemine esmase haiglaravi jooksul. 
Aktiivsema perinataalabi käsitluse, VVGV laste elulemuse suurenemise ja 
vähem invasiivse neonataalravi rakendamisega ei kaasnenud aastatel 2007 
2008 haiglaravi kestuse suurenemist võrreldes aastatega 20022003. 
Mitmesel regressioonanalüüsil olid peamised riskitegurid surmaks väike 
gestatsioonivanus sünnil (OR 0.66; 95% CI 0.57–0.75), 1. eluminuti Apgari 
hinne < 5 (2.67; 1.49–4.79) ja III–IV astme (peri)intraventrikulaarse hemor-
raagia esinemine (8.79; 4.71–16.42). 
 
VVGV enneaegsete laste ravi hilistulem enneaegsusele korrigeeritud  
2 aasta vanuses 
Uuringus III ja IV osalenud VVGV kohordis oli mitmikute osakaal suurem kui 
ajalisena sündinud laste võrdluskohordis. Samuti olid VVGV lapsed enam pärit 
madala haridustaseme ja sissetulekuga peredest. VVGV laste keskmine vanus 
rinnapiimaga toitmise lõpetamisel oli oluliselt väiksem (147 vs 308 päeva;  
p  0,001) ja lastekollektiivi minekul oluliselt suurem (22,2 vs 20,4 kuud;  
p  0,001) kui ajalisena sündinud lastel. 
Järelkontrollil olid 60% VVGV lastest arengus järele jõudnud ajalisena sün-
dinud eakaaslastele ning neil ei esinenud nägemis- ja kuulmispuuet. Mõõdukas/ 
raske arenguhäire esines 12%-l VVGV lastest: tserebraalparalüüs 8%-l, kogni-
tiivse arengu mõõdukas/raske mahajäämus 5%-l, kõne arengu mõõdukas/raske 
mahajäämus 10%-l ja kuulmispuue 1%-l. Vaid üks laps oli pime ühest silmast. 
Väike kaal ( 10 protsentiili) esines kolmandikul ja lühike pikkus ning väike 
peaümbermõõt ligikaudu viiendikul VVGV lastest. 
VVGV laste tervisetulem oli halvem kõikides uuritud valdkondades võrrel-
des ajalisena sündinud lastega. Enneaegsete laste kõik kolm kasvumõõtu (keha-
kaal, pikkus ja peaümbermõõt) olid statistiliselt tõepäraselt väiksemad kui aja-
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liselt sündinud lastel. Bayley testi alusel hinnatud kognitiivse, kõne ja motoorse 
arengu keskmine koondskoor oli VVGV lastel 0,5 SD võrra madalam kui 
ajalisena sündinud lastel. Enneaegsetel lastel oli eriti täheldatav kõne arengu 
hilinemine. Keskmiste koondskooride vahe VVGV ja ajalistel lastel püsis 
muutumatuna kohandamisel pere sissetulekule, pere struktuurile ja vanemate 
haridusele ning vähenes, kuid jäi statistiliselt tõepäraseks, kui analüüsist arvati 
välja tserebraalparalüüsi ning raske nägemis- ja kuulmispuudega lapsed. III 
etapi naistekliinikutes sündinud VVGV laste kognitiivse ja motoorse arengu 
keskmised koondskoorid olid oluliselt kõrgemad kui maakonnahaiglates 
sündinud VVGV lastel. 
Mitmesel regressioonanalüüsil leiti peamised riskitegurid ebasoodsaks tule-
miks enneaegsusele korrigeeritud 2 aasta vanuses (kaal  10 protsentiili, 
GMFCS-skaala 2.5. astmega tserebraalparalüüs, kognitiivne areng  -2 SD, 
kõne areng  -2 SD ja/või mõõdukas/raske arenguhäire). Nendeks osutusid 
antenataalse glükokortikoidravi puudumine, neonataalsel aju ultraheliskriinin-
gul diagnoositud IIIIV astme (peri)intraventrikulaarne ajuhemorraagia ja/või 
IIIV astme periventrikulaarne leukomalaatsia, bronhopulmonaalse düsplaasia 
ja/või nekrotiseeriva enterokoliidi põdemine esmasel haiglaravil ning eba-
rahuldav kaaluiive sünnijärgses perioodis. Gestatsioonivanus pideva tunnusena 
oli oluliseks riskiteguriks koondtulemile mõõduka/raske arenguhäirena, kuid 
mitte väikese kaalu, tserebraalparalüüsi, kognitiivse arengu mahajäämuse ja 
kõne arengu mahajäämuse esinemisele laste 2 aasta vanuses. 
 
VVGV enneaegsete laste äge respiratoorne haigestumus kahel esimesel 
eluaastal 
Haigestumus ägedatesse respiratoorsetesse infektsioonidesse ei erinenud VVGV 
ja ajaliste laste seas. Esimesel eluaastal esines mõlemas grupis keskmiselt 1,5 ja 
teisel eluaastal 1,9 ägeda respiratoorse infektsiooni juhtu. Küll aga esines 
esimesel eluaastal ägedat respiratoorset haigestumist oluliselt enam  28 GN 
sündinud lastel kui küpsematel enneaegsetel ja ajalistel lastel. Ägeda respira-
toorse haigestumise ajal esines VVGV lastel oluliselt enam vilistavat hingamist 
ning nad vajasid ka enam antibakteriaalset ja haiglaravi. 
Mitmesel regressioonanalüüsil oli ägeda respiratoorse haigestumise ebasood-
sa kulu (ühekordne vilistav hingamine, korduv vilistav hingamine ja/või hospi-
talisatsiooni vajadus) olulisteks riskiteguriteks ema madal haridustase, mees-
sugu, enneaegsus ja bronhopulmonaalse düsplaasia põdemine esmasel haigla-
ravil, kusjuures ainsaks oluliseks riskiteguriks kõikidele ägeda respiratoorse 
haigestumise ebasoodsa kulu tunnustele oli bronhopulmonaalse düsplaasia 
esinemine. 
 
Järeldused 
1. Uuritavatel ajaperioodidel, 20022003 vs 20072008, püsis VVGV elus-
sündide osakaal Eestis muutumatuna, kuid oluliselt suurenes VVGV vast-
sündinute intensiivravile suunamine (94 vs 98%) ja laste elulemus esmase 
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haiglaravi lõpuni (78 vs 85%). VVGV laste elulemuse suurenemine saavutati 
aktiivsema perinataalraviga ja vähem agressiivse vastsündinute raviga. 
Aastatel 20072008 esinesid keskustevahelised erinevused sünnijärgsete 
hingamishäirete varases ravitaktikas. Elulemuse paranemisega ei kaasnenud 
hilisemaid puudeid ennustavate haigustega elulejate osakaalu suurenemist 
ega haiglaravi kestuse pikenemist. 
2. 2007. aastal sündinud ja enneaegsusele korrigeeritud 2 aasta vanuses uuritud 
VVGV lastest 12%-l esines mõõdukas/raske arenguhäire; 60% oli arengus 
järele jõudnud ajalisena sündinud lastele. Bayley testi alusel hinnatud 
kognitiivse, kõne ja motoorse arengu keskmine koondskoor oli VVGV lastel 
0,5 SD võrra madalam kui ajalisena sündinud lastel. VVGV laste kõik kolm 
kasvumõõtu (kehakaal, pikkus ja peaümbermõõt) olid statistiliselt tõe-
päraselt väiksemad kui ajaliselt sündinud lastel. VVGV lastel esines ägeda 
respiratoorse haigestumise korral oluliselt enam vilistavat hingamist ning 
antibakteriaalse ja haiglaravi vajadust. 
3. VVGV enneaegsete laste ebasoodsa hilise tervisetulemi peamiseks riski-
teguriks oli hilisemaid puudeid ennustavate neonataalsete haiguste põdemine 
esmasel haiglaravil, kusjuures bronhopulmonaalse düsplaasia põdemine oli 
ainsaks oluliseks riskiteguriks laste ägeda respiratoorse haigestumise eba-
soodsa kulu kõikidele tunnustele. 
4. Perinataalabi ja vastsündinute intensiivravi kvaliteeti Eestis saab hinnata 
rahuldavaks. VVGV laste elulemus Eestis on võrdväärne teiste arenenud 
meditsiiniabiga riikidega, kuid laste varane haigestumus ja tervisehäirete 
esinemine 2 aasta vanuses jääb osaliselt suuremaks. 
5. Peri- ja neonataalabi peamiseks ülesandeks Eestis on vähendada VVGV 
enneaegsete neonataalset haigestumist, säilitades suure elulejate osakaalu. 
Ravikvaliteedi edasiseks parandamiseks on vajalik ravitaktika ühtlustamine 
riikliku tõenduspõhise enneaegse sünnituse ja vastsündinu käsitlusjuhise 
väljatöötamisega ning väga enneaegsete sünnituste jätkuv koondamine III 
etapi raviasutustesse. Oluline on perinataalkeskuste loomine, et tagada loote 
ja vastsündinu tõenduspõhise ravi järjepidevus ning välistada VVGV enne-
aegsete transport vahetus sünnijärgses perioodis. Nüüdisaegse kiiresti muu-
tuva perinataalabi ja vastsündinute intensiivravi tingimustes tuleb leida või-
malus väga enneaegsena sündinud laste ravikvaliteedi järjepidevaks seireks 
Eestis.  
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